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A B S T R A C T
Background
Patients with Parkinson’s disease commonly suffer from speech and voice difficulties such as impaired articulation and reduced loudness.
Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental
aids.
Objectives
To compare the efficacy and effectiveness of novel SLT techniques versus a standard SLT approach to treat Parkinsonian speech problems.
Search methods
We identified relevant, published prior to 11th April 2011, by electronic searches of numerous literature databases includingCENTRAL,
MEDLINE and CINAHL, as well as handsearching relevant conference abstracts and examining reference lists in identified studies
and other reviews.
Selection criteria
Only randomised controlled trials (RCT) of one type of speech and language therapy versus another were included.
Data collection and analysis
Two review authors independently extracted data and resolved differences by discussion.
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Main results
Six trials involving 159 patients satisfied the inclusion criteria. Data could not be analysed from one trial due to changes in patient
numbers and from a second because the data provided were not in a usable format. All trials reported intelligibility measures but a
statistically significant result was only reported for the diagnostic rhyme test used in the study of Lee SilvermanVoice Treatment -LOUD
(LSVT-LOUD) versus a modified version of this therapy (LSVT-ARTIC). In this case a difference of 12.5 points (95% confidence
interval (CI) -22.2 to -2.8; P = 0.01) between the mean changes in favour of the LSVT-LOUD group was reported for a speech sample
overlaid with Babble noise; this difference was not reproduced for the two additional noise conditions under which the speech samples
were assessed. LSVT-LOUD also outperformed LSVT-ARTIC and Respiration therapy (RT) in improving loudness, with a difference
in reading a sample text of 5.0 dB (95%CI -8.3 to -1.7; P = 0.003) and 5.5 dB (95% CI 3.4 to 7.7; P < 0.00001) respectively, and a
difference in monologue speech of 2.9 dB (95% CI 0.6 to 5.2; P = 0.01) versus RT.
Authors’ conclusions
Considering the small patient numbers in these trials, there is insufficient evidence to support or refute the efficacy of any form of SLT
over another to treat speech problems in patients with Parkinson’s disease.
P L A I N L A N G U A G E S U M M A R Y
Speech and language therapy for speech problems in Parkinson’s disease
Many people with Parkinson’s disease suffer from disorders of speech. The most frequently reported speech problems are weak, hoarse,
nasal or monotonous voice, imprecise articulation, slow or fast speech, difficulty starting speech, impaired stress or rhythm, stuttering
and tremor. People with the condition also tend to give fewer non-verbal cues such as using facial expression to convey information.
These disabilities tend to increase as the disease progresses and can lead to serious problems with communication.
This review compares the benefits of one form of speech and language therapy (SLT) versus another for individuals with Parkinson’s
disease. Relevant trials were identified by electronic searches of 16 biomedical literature databases, various registers of clinical trials and
examination of the reference lists of identified studies and other reviews.
Only randomised controlled trials were included in this review. These are studies in which two groups of patients were compared, each
group receiving a different form of SLT, with patients assigned to the groups in a random fashion to reduce potential for bias.
Six trials were found with a total of 159 patients. Methods varied so much that meta-analysis of the results was not possible. Considering
the small number of patients and the methodological flaws in these studies, there is insufficient evidence to support the use of one form
of SLT over another for the treatment of speech problems in individuals with Parkinson’s disease.
B A C K G R O U N D
For definition of terms see Table 1: Glossary.
Speech problems are common in Parkinson’s disease (PD) and in-
crease in frequency and intensity with progression of the disease
(Streifler 1984; Sapir 2001). Dysarthria is a collective name for a
group of speech disorders resulting from disturbances in muscular
control of the speech mechanism due to damage of the central
nervous system. It designates problems in oral communication
due to paralysis, weakness or incoordination of the speech mus-
culature (Darley 1969). Common characteristics of Parkinsonian
dysarthria are monotony of pitch and volume (dysprosody), re-
duced stress, imprecise articulation, variations in speed resulting
in both inappropriate silences and rushes of speech, and a breathy
hoarseness to the speech (hypophonia) reflecting the difficulty the
patient has in synchronising talking and breathing (Logemann
1978; Stewart 1995). Many of these features are attributed to hy-
pokinesia (paucity of movement) and rigidity which are consid-
ered to be cardinal features of PD (Mawdsley 1971). Patients with
PD also suffer from cognitive impairment which leads to difficul-
ties in language selection, language understanding, coordination
and dual tasks (talking and walking) as well as emotional intent
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and understanding. These issues do not come under the umbrella
of dysarthric speech but impact on the ability of individuals to
participate in spoken communication. As a result, the title of this
review has been changed from ‘dysarthria’ to include the full com-
plexity of ‘speech problems’ in PD.
Four approaches to speech therapy are available: behavioural treat-
ment techniques (drill, exercise), instrumental aids including pros-
thetic and augmentative devices, medication, and surgical proce-
dures. Pharmacotherapy and surgery have a limited role in the
management of specific motor impairments such as speech dis-
orders, particularly those that emerge during the later stages of
the disease. It has been suggested that the behavioural treatment
techniques of speech and language therapy (SLT) may be more ef-
fective in improving the intelligibility of speech in Parkinson’s dis-
ease. Even then, “compensated intelligibility” rather than “normal
speech”may be considered themore limited goal of SLT (Rosenbek
1985).
A 2009 patient survey by Parkinson’s UK showed that only 34% of
patients with PD in England reported receiving SLT (Parkinson’s
disease society 2008). This low referral rate does not accord with
the advice in most published guidelines which suggests that SLT
should always be made available for the management of PD (
NCC-CC 2006).
This review compares the efficacy of one type of speech and lan-
guage therapy with another for speech problems in patients with
PD. Another review examines trials that compare speech and lan-
guage therapy with placebo or no intervention (Herd In Press).
O B J E C T I V E S
To compare the efficacy and effectiveness of novel SLT techniques
versus an alternative SLT approach in patients with PD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials comparing two
types of speech and language therapy for inclusion in the study.We
accepted both random and quasi-random methods of allocation.
Types of participants
• Patients with a diagnosis of PD (as defined by the authors
of the studies)
• Any duration of PD
• All ages
• Any drug therapy
• Any duration of treatment
Types of interventions
One speech and language therapy technique versus a second.
Types of outcome measures
1. Speech and voice production parameters (i.e. measures of im-
pairment).
(a) Total impairments (e.g. Dysarthria rating scales, Intelligibility
rating scales).
(b) Objective and subjective acoustic measures of speech samples
(e.g. pitch, loudness, sentence length etc.).
(c) Measures of laryngeal activity (e.g. fibre optic laryngoscopy,
stroboscopy).
(d) Level of communication participation.
2. Activities of daily living (e.g. Sickness Impact Profile (SIP) com-
munication subsection (Bergner 1981)).
3.Handicap and quality of lifemeasures, both disease-specific (e.g.
Parkinson’s Disease Questionnaire - 39, PDQ39) and generic (e.g.
Short Form - 36, SF36).
4. Depression rating scales (e.g. Beck Depression Index (BDI)
(Beck 1961)).
5. Adverse effects.
6. Carer outcomes (e.g. Carer strain index).
7. Economic analysis.
We examined both the short-term and the long-term effects of the
interventions.
Search methods for identification of studies
1. The review is based on the search strategy of the Movement
Disorders Group and also the following more general search strat-
egy:
a. Dysarthria OR speech OR speak OR intelligibility OR dys-
prosody OR hypophonia OR monotonicity OR phonate
b. ((Speech OR speak OR language OR voice OR vocal OR ar-
ticulate OR sing) near (task OR therapy OR treatment OR train
OR councel OR intervention OR exercise OR drill OR rehabili-
tation)) OR silverman OR LSVT
c. Parkinson OR Parkinson’s disease OR Parkinsonism
d. (#a AND #b AND #c) OR (#a and #c)
See Appendix 1 for sample search (MEDLINE). This strategy was
adapted for each electronic database.
We identified relevant trials by electronic searches of general
biomedical and science databases: The Cochrane Controlled Tri-
als Register (CENTRAL) searched without date limiters, CEN-
TRAL (MEDLINE database searched throughOvid (1966-2011)
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and PubMed (2010-2011 for data not yet released onto Ovid
Medline), EMBASE (1974-2011), CINAHL (1982-2011), ISI-
SCI ((1981-2011); rehabilitation databases: AMED (1985-2011),
MANTIS (1880-2000), REHABDATA (1956-2011), REHA-
DAT, GEROLIT (1979-2011); English language databases of
foreign language research and third world publications: Pascal
(1984-2000), LILACS (1982-2011), MedCarib (17th Century-
2000), Journal@rchive (19th century-2011), AIM (1993-2000),
IMEMR (1984-2011) and handsearching of appropriate confer-
ence proceedings Relevant trials were included on the Group’s spe-
cialised register of randomised controlled trials.
2. We also searched The CenterWatch Clinical Trials listing
service, controlled_trials.com, ClinicalTrials.gov, CRISP, PEDro,
NIDRR and NRR for relevant trials.
3. The reference lists of located trials and review articles.
4. Grey literature (e.g. conference abstracts, theses and inter-
nal reports) were searched. This included The International
Congress on Parkinson’s disease (1999, 2001), The International
Congress of Parkinson’s Disease and Movement Disorders (1990,
1992, 1994, 1996, 1997, 1998, 2002, 2004, 2005, 2006, 2007,
2008, 2009, 2010, 2011), The American Academy of Neurol-
ogy 51st annual meeting (1999) and the Congress of the Eu-
ropean Federation of Neurological Societies (2003, 2004, 2005,
2006, 2007, 2008, 2009, 2010). We searched the following grey
literature databases: OpenSIGLE (1980-2011), ISI-ISTP (1982-
2000), Proquest(1999-2011), Conference Papers Index (1982-
2011) Ethos (1970 -2011) and Index to Theses (1716 - 2011).
Further details on this search strategy are available in the Group’s
module within The Cochrane Library (www.cochrane.org). This
includes explanations of the acronyms, sources and web sites.
Data collection and analysis
The review authors independently assessed the studies identified
by the search strategy.We resolved disagreements about inclusions
by discussion.
We contacted the authors of trials in the cases where further trial
information was required for full analysis. We assessed full papers
formethodological quality by recording themethod of randomisa-
tion, concealment of allocation and blinding of assessors to treat-
ment group, whether an intention-to-treat analysis was used and
the number of patients lost to follow-up.
Two review authors (CPH and CLT) independently abstracted
eligible data onto standardised forms, checked for accuracy and
amalgamated the information. We resolved disagreements about
inclusions by discussion.
We combined the results of each trial using standard meta-analytic
methods to estimate an overall effect for one type of speech and
language therapy intervention versus another.
For all identified continuous variables, we calculated the mean
difference between treatment arms using weighted mean differ-
ence methods (Fleiss 1993). In summary, this involved for each
trial, calculating the mean change (and standard deviation) from
baseline to the post-intervention time point for both intervention
groups. The mean difference and its variance between arms for
each trial could then be calculated. In some studies the standard
deviation for the mean change was not reported, in these cases,
we imputed this standard deviation using the standard deviations
for the baseline and final scores. To do this we used the following
formula to estimate the variance of the change in score:
var diff = var pre + var post - 2r
√
(var pre var post )
where var diff is the variance of the change score; var pre is the
variance of the baseline score; var post is the variance of the final
score and r is the correlation between the pre- and post- treatment
scores. We assumed a correlation co-efficient of 0.5, which is a
conservative estimate, to reduce the chance of false positive results
(Higgins 2011).
We then combined these values using weighted mean difference
methods to give the overall pooled estimate of themean difference,
with 95%confidence interval, for one speech and language therapy
intervention versus another. A result with a value of P < 0.05 is
considered to be statistically significant.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See Table 2: Characteristics of included studies and Figure 1:
PRISMA flow diagram.
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Figure 1. PRISMA diagram.
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We found five randomised controlled trials comparing two meth-
ods of speech and language therapy for speech disorders in a total
of 125 patients with PD (Scott 1983; Ramig 1995; Healy 2002;
Halpern 2007; Lowit 2010). In addition to this, we included a trial
of 34 patients that compared two different delivery methods for
the same speech and language therapy technique (Constantinescu
2011).
Trial design
Five trials (Scott 1983; Ramig 1995; Healy 2002; Halpern 2007;
Constantinescu 2011) were parallel group trials; four were single-
centre studies and one was a multi-centre study; and one trial
(Lowit 2010) had a cross-over design, fromwhich we included the
pre-cross-over data in this review.
Participants
Scott 1983, the mean age of the patients was 66 years in both
groups, but the visual stimulation group had only two females
(of 13), whereas the prosodic exercises group had seven (of 13).
The stage of PD was not assessed. In Ramig 1995, the 45 patients
were stratified by a large number of criteria including age, sex
and stage of disease before randomisation. This lead to the ages
of the participants in the two groups being similar (64 and 66
years) as was the disease stage (Hoehn and Yahr 2.7 and 2.3).
However, the split of the sexes was uneven with the Lee Silverman
Voice Treatment (LSVT) group having 19% females whilst the
respiration therapy group had 37%. The two groups in Lowit
2010 were age-matched at an average of 63 years. There was a large
difference inHoehn and Yahr scores and male/female ratio for this
trial with the Altered Auditory Feedback group scoring an average
of 1.8 at baseline and having only one in five females and the
Traditional Therapy group score averaging 3.3 with three in five
patients being female. Stratification parameters used in Halpern
2007 ensured an even distribution of female participants across
the two groups (two in LSVT-ARTIC and three in LSVT-LOUD)
and matched the groups for age with an average of 66 and 71
for LSVT-ARTIC and LSVT LOUD respectively and Hoehn and
Yahr score (on medication) for which both groups averaged 2.2.
The groups taking part in Constantinescu 2011 were matched in
age 70.5 (LSVT Artic), 66.1 (LSVT LOUD), male/female ratio
6/2 (LSVT Artic), 7/3 (LSVT LOUD) and Hoehn and Yahr stage
on medication score 2.2 (LSVT Artic) and 2.2 (LSVT LOUD).
Duration of condition was not reported for this study. Baseline
characteristics for the four groups inHealy 2002were not reported,
the mean age of all participants was 65.6. Of the 26 participants
in this trial, nine were female.
Interventions
See Table 3: Summary of Interventions
Scott 1983 treated their patients for 10 hours over two weeks.
Ramig 1995 andConstantinescu 2011 treated their patients for 16
hours over onemonth. Halpern 2007 delivered a similar treatment
schedule of 16 sessions lasting 50 minutes each over one month.
Lowit 2010 providedweekly hour-long sessions for sixweeks. Scott
1983 and Lowit 2010 treated their patients at home and Ramig
1995, Halpern 2007 and Constantinescu 2011 conducted their
therapy in anoutpatient setting.Healy 2002 split their participants
between four groups and for each of the two interventions there
was a group who received a single hour-long session and a group
who received six sessions, each an hour-long over six weeks.
A variety of intervention methods were used in the studies: Scott
et al considered the Parkinsonian speech abnormality to be a dys-
prosody (see Glossary Table 1). It is responsible for conveying sub-
tle changes of meaning independently of word or grammatical or-
der. In addition to this semantic role, it makes a major contribu-
tion to the emotional content of speech. Scott 1983 used prosodic
exercises (PE) aimed at improving the patients’ prosodic abnor-
mality by increasing their awareness of the problem and empha-
sising the importance of volume and intonation. The other arm
of the study used the same prosodic exercises but also gave the
patients visual feedback using a ’Vocalite’. The Vocalite is a voice-
operated light source designed to enable the patient to monitor
some of the prosodic features of their own speech. The trial there-
fore examined the influence of the Vocalite only.
Ramig 1995 used respiration therapy (RT) aimed at increasing res-
piratory muscle activity, thus increasing respiratory volumes and
subglottal air pressure. Patients were given visual feedback of their
rib cage and abdominal movements via a ’Respigraph’ in some
of their treatment sessions. The other arm of the study used the
LSVT method. LSVT is a high effort intensive treatment that
aims to increase vocal loudness through increasing vocal adduc-
tion, ’thinking loud’ and increasing respiratory effort; it is some-
times referred to as LSVT-LOUD. These techniques were also
used by Halpern 2007 where the comparison was LSVT-LOUD
versus LSVT-ARTIC, which uses broadly the same techniques as
LSVT-LOUD but with the cue ‘Enunciate’ to focus on articula-
tion. LSVT-LOUD was also studied by Constantinescu 2011 in
a non-inferiority trial investigating the efficacy of online delivery
of the techniques compared with traditional face-to-face delivery.
Speech rate reduction was the focus of the Lowit 2010 trial and an
in-ear device was used which altered the way a speaker hears their
own voice by changing the pitch or delaying the sound. The con-
trol arm in this trial was traditional rate reduction therapy using
behavioural techniques of pause insertion or stretching out artic-
ulation. Healy 2002 also studied two rate reduction techniques.
Two of the groups were trained with an alphabet chart, in an at-
tempt to control their rate of speech they were instructed to point
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to the initial letter of each word they said on the chart. The re-
maining two groups used a pacing board which is divided into
sections, the speaker places their finger into each section consecu-
tively for each word spoken.
Outcome measures
Scott 1983 measured prosodic abnormality and intelligibility.
Ramig 1995 measured a very wide variety of outcomes. Ob-
jective and subjective measures of intelligibility, volume, mono-
tonicity and an objective measure of pitch were included, as well
as measures of depression (Beck Depression Index (BDI) (Beck
1961)); and activities of daily living that were affected by poor
speech asmeasuredwith the communication and social interaction
subsections of the Sickness Impact Profile (SIP) (Bergner 1981).
Constantinescu 2011 measured a variety of outcomes including
acoustic measures of loudness during a variety of speech formats,
acoustic frequency and perceptual measures of loudness and in-
telligibility. Halpern 2007 measured loudness and intelligibility
using the diagnostic rhyme test (DRT) and Lowit 2010 measured
speech rate and intelligibility from long connected speech tasks.
Healy 2002 reported measures of speaking rate and intelligibility
for a variety of speaking modes as well as results of an oro-motor
assessment for whichmovement of lips, tongue and soft palate and
voice quality are rated. This study group also included reported
level of voluntary use of devices outside of therapy sessions as an
outcome measure.
Risk of bias in included studies
See Table 2 and Figure 2 for summary of themethodological qual-
ity of the trials.
It is impossible to blind patients and treating therapists in trials
comparing the efficacy of two types of speech and language ther-
apy. This leaves such trials open to performance and attrition bias.
Blinded assessors were used for all included trials, so detection bias
is unlikely in these studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Randomisation method and concealment of
allocation
Scott 1983 used random number tables to randomise the patients.
Although the therapist was blinded to the treatment group, the al-
locationwas carried out by one of the authors of the paper. Personal
communication with the authors revealed that this author saw
only a few patients, therefore, the chance of selection bias is small.
Ramig 1995 pulled numbers out of a hat to randomise patients
into their trial and Healy 2002 used sealed envelopes. Though
these are a truly random methods, they are open to manipulation
as concealment of allocation can easily be compromised. Halpern
2007 and Constantinescu 2011 both used computer-generated
random number allocation. Concealment of allocation was not re-
ported for either of these trials, therefore, cannot be confirmed and
selection bias cannot therefore, be ruled out, despite the use of a
sophisticated method to generate the allocation. Lowit 2010 used
alternate allocation to randomise.This method is poor as it is not
truly random and concealment of allocation cannot be achieved
thus, there is a high risk of selection bias.
Eligiblity criteria
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The eligibility criteria for the trials were broad. Scott 1983 treated
patients with PD who had a speech disorder. They excluded those
they considered to have a ’subjectively slight’ communication dis-
order, intellectual impairment, history of stroke or other disorder
likely to affect speech, significant hearing impairment, or those
with varying drug therapy. Ramig 1995 excluded patients without
idiopathic PD or with laryngeal pathology. The authors rated their
patient’s speech deficits on a five-point scale along with their pri-
mary speech and/or voice characteristics at baseline. Healy 2002
included patients with a diagnosis of PD who were able to cope
with individual therapy sessions. They also required participants
to have a faster than normal speech rate or evidence of ‘palilalia’
(see Glossary Table 1), with or without other dysarthric features.
Exclusion criteria for this trial were a score of nine or below on
the Middlesex Elderly Assessment of Mental State ((MEAMS);
Golding 1989); unclear diagnosis of PD; recent or anticipated
change in Parkinsonian-related medication; previous exposure to
the pacing techniques used in this study. Halpern 2007 stated only
that patients had PD. Inclusion criteria for Lowit 2010 were a di-
agnosis of idiopathic PD and a speech impairment severe enough
to warrant treatment. Patients were excluded if there was a pres-
ence of significant dementia, history of deep brain stimulation or
speech and language therapy for dysarthria symptoms during the
previous 12 months or presence of speech and language problems
other than those caused by PD. Constantinescu 2011 included
patients with a diagnosis of hypokinetic dysarthria (mild to severe)
with PD impacting on communication, a videolaryngoscopic eval-
uation of the vocal fold structure and movement consistent with
PD, with the ability to produce speech of an increased loudness
when guided to do so and on a consistent drug regimen for PD.
Exclusion criteria for this group consisted of speech or language
difficulties unrelated to PD, an additional co-existing neurological
disorder, respiratory difficulties inconsistent with PD, cognitive
difficulties resulting in the inability to provide informed consent,
a severe uncorrected visual and/or auditory disturbance, a history
of alcohol abuse or participation in LSVT within 12 months of
this study.
Patient numbers
We found only six randomised controlled trials comparing two
methods of speech and language therapy for speech disorders in a
total of 159 Parkinson’s patients (see Table 2 for patient numbers
in each trial). With such a small number of patients examined, it is
possible that there was bias in the selection of patients, therefore,
the applicability of the data to the general population with PD
is questionable. The lack of power due to the small number of
patients also increases the risk of a false negative result.
Similarity at baseline
In all trials, females were under-represented (only 28%) while in
the general Parkinson’s population, the incidence is around 50%.
Scott 1983 gave no indication of the severity of PD for its patients.
It is accepted that the Hoehn and Yahr score assesses physical
disability and does not have a speech component and so would be
a very crude measure of speech impairment. However, it has been
shown that impairment in speaking ability increases in frequency
and intensity with the progress of the disease (Streifler 1984;
Sapir 2001). Scott 1983 did not give a measure of overall speech
impairment, whilst Ramig 1995 used a five-point rating scale to
summarise the speech impairments of the patients. Matching of
baseline characteristics between the two arms is difficult to achieve
for the small groups studied in the trials included in this review.
This is highlighted in Lowit 2010 as there is a difference of 1.5
points between the average Hoehn and Yahr scores for the two
groups. Healy 2002 could not be analysed for similarity as baseline
characteristics for the groups were not provided.
Description of speech and language therapy methods
It is important that other speech and language therapists have
enough details of the methods used in the studies to be able
to reproduce them accurately. The methods of speech and lan-
guage therapy were all described in broad terms in the papers.
Ramig 1995 and Scott 1983 also referred readers to books that
detailed the prosodic exercises (Halliday 1970) and LSVT (Ramig
1995b) in greater depth. The respiration therapy used in Ramig
1995 was also well referenced. A website reference was provided
for further details of the in-ear devices used in Lowit 2010 (
www.casafuturatech.com). .
One speech and language therapist administered treatment to both
groups in Scott 1983. Clinicians were randomly assigned to pa-
tients in Ramig 1995 and Constantinescu 2011 to deliver either
high treatment; daily homework was given out to patients in these
trials. Two therapists were involved in the delivery of treatment in
Ramig 1995 and four therapists in Constantinescu 2011. Thera-
pists involved in Healy 2002 instructed patients on the use of two
rate-control devices in either a single session or six sessions and
then patients were encouraged to practice with the devices dur-
ing their daily activities. Halpern 2007 and Lowit 2010 did not
discuss the number or the type of health professionals involved in
delivery of their interventions.
Drug therapy
The drug therapy of the patients was constant in Scott 1983 and
Halpern 2007, but in Ramig 1995 the drug therapy was only
kept constant for the duration of the speech and language ther-
apy. During the two-year follow-up period the patients were ’op-
timally medicated’. Although various drug therapies can affect
speech quality (Biary 1988; Dann 1994; Stewart 1995), this is
ethically unavoidable in a trial of this length. Lowit 2010 stated
that two of the 10 participants in their trial had changed their drug
regimen during the treatment phase; the group assignments for
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these two patients were not reported. Although Constantinescu
2011 stated in their inclusion criteria that a stable drug regimen
was required they failed to report whether or not the participants
maintained this throughout the trial period. Healy 2002 did not
report details of whether drug therapies were constant throughout
the trial period for their patients.
Data analysis
This review discusses differences between the effectiveness of one
type of SLT and an alternative, as such, there is no distinction in
our analysis between two therapies which have both improved an
outcome and two therapies which have both had no effect or made
things worse, all are reported as ‘no difference’. For a discussion of
the effectiveness of these techniques see Cochrane review ‘Speech
and language therapy for speech problems in Parkinson’s disease’(Herd
In Press).
Scott 1983, Ramig 1995 and Lowit 2010 analysed data on a per
protocol basis rather than on an intention-to-treat basis. This com-
promises the randomisation and could lead to attrition and de-
tection bias. In Lowit 2010, one patient withdrew from the TT
group after baseline assessment. In Ramig 1995 after 24 months,
seven of the 19 patients who started in the RT group and five of
the 26 patients in the LSVT group, had withdrawn from the study.
Interpretation of the results from this trial was further complicated
by subsets of the patients being examined in greater detail for cer-
tain parameters (e.g. laryngoscopic analysis, aerodynamic analysis,
perceptual voice quality analysis). It is not made clear which of
the original 45 patients were examined in each of these subsets.
In Scott 1983, two of the final 12 patients were missing from the
baseline assessment in their PE-only group. Halpern 2007 and
Constantinescu 2011 had no withdrawals and so it is assumed
they used an intention-to-treat design in their protocol, although
this was not stated. It was unclear from the information provided
whether any patients withdrew from Healy 2002.
Only Constantinescu 2011 statistically compared the change in a
given outcome measure (i.e. score after therapy - score at baseline)
between the two therapy groups (i.e. change due to therapy A ver-
sus change due to therapy B). All other trials statistically compared
the change in an outcome for each therapy group individually over
time. This means that these trials do not examine whether one
form of SLT is better than another, only that improvements oc-
curred after a given therapy. The results from four trials were anal-
ysed for statistical significance. Outcomes from Scott 1983 and
Healy 2002 could not be included in this due to missing baseline
data and data provided in a non-usable format respectively.
Effects of interventions
See Summary of Results Tables: Table 4; Table 5; Table 6; Table
7; Table 8. Significant results are statistically significant at the P
< 0.05 level. The trial designs of the identified studies were so
different that meta-analysis of the results was inappropriate.
Scott 1983
Therapists involved in Scott 1983 assessed tapes of the 23 pa-
tients’ speech. They used a seven-point prosodic abnormality
score, which assessed volume, pitch, tone, intonation, vocal quality
(hoarseness, tremor etc), rate and rhythm. One point was scored
for an abnormality of any item, zero if normal. Scott 1983 mea-
sured intelligibility in two ways, firstly using an ad hoc rating scale
(zero to three) and secondly with a visual analogue scale (zero to
100). Scott 1983 concentrated solely on prosody and intelligibil-
ity as outcome measures in this study. No other outcomes were
measured. The statistical significance of all Scott 1983 outcome
measures could not be assessed as an additional patient was in-
cluded in the exercises-alone group post-treatment data sets.
Ramig 1995
Ramig 1995 was unique in following their patient groups for two
years. Unfortunately, the data were analysed in a per-protocol
rather than intention-to-treat manner. From the 45 patients that
started the trial, 12 patients withdrew at later time points and
were removed from the baseline data in subsequent publications.
Potentially the baseline data could have shifted over time due to
these withdrawals.
Intelligibility was assessedwith a visual analogue scale (zero to 100)
as used in Scott 1983, but in this study, ratings were carried out
by the patients themselves and their carers prior to treatment and
immediately post-treatment. The differences in the change of the
mean intelligibility scores between the RT group and the LSVT
group were not statistically significant (P = 0.5 as assessed by the
patients and P = 0.24 as assessed by the carers).
For objective outcomes, loudness was described as sound pressure
level (SPL) or intensity (see Glossary: Table 1). Patients and carers
assessed loudness on a 100-point visual analogue scale. There was
no difference in the change of the mean scores between the treat-
ment groups (P = 0.64 as assessed by the patients or P = 0.88 as as-
sessed by the carers). The mean objective loudness of the patient’s
monologue improved by 2.9 dB (95% confidence interval (CI)
0.6 to 5.2; P = 0.01) more with LSVT than with RT immediately
after treatment. This significant result was maintained 12 months
later with a reported 3.8 dB (95% CI 1.2 to 6.4; P = 0.004) differ-
ence between the two groups. After 24 months, the difference was
no longer significant (P = 0.44). A similar pattern was observed in
the loudness of the patients’ voices reading a standard passage (the
Rainbow Passage). Immediately after LSVT, the patient’s reading
loudness improved by 5.5 dB (95% CI 3.4 to 7.7; P < 0.00001)
when compared with RT and at 12 months the difference was
2.8 dB (95% CI 0.2 to 5.4; P = 0.03). The difference between
therapy groups was no longer significant at 24 months (P = 0.08).
For sustained phonation, the difference between the two groups
was significant at 14.3 dB (95% CI 11.5 to 17.0; P < 0.00001)
immediately after treatment and was maintained at 12 months
(9.5 dB; 95% CI 6.0 to 13.0; P < 0.00001) and 24 months (7.3
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dB; 95% CI 3.3 to 11.3; P = 0.0004) after treatment.
Monotonicity was assessed by patients and their carers on a visual
analogue scale in Ramig 1995. The difference in the change of the
mean monotonicity scores between the groups was not significant
in both cases (P = 0.2 as assessed by the patients and P = 0.78 as
assessed by the carers). The objective measure of monotonicity was
fundamental frequency (pitch) variability (see Glossary: Table 1).
This is a measure of the standard deviation of the lowest pitch of
a patient’s voice over a period of time. In this case it was measured
in semitones (ST) for monologue speech and reading a passage.
During a monologue the groups’ speech varied by 0.47 semitones
(95% CI 0.01 to 0.93; P = 0.04) more with LSVT than with RT
immediately after treatment. This difference was maintained 24
months later, when it was 0.77 semitones (95%CI 0.06 to 1.48; P
= 0.03). No difference was observed in the pitch variability of the
patients’ voice when reading a standard passage (the Rainbow Pas-
sage) immediately after treatment. Follow-up assessments of this
outcome up to 24 months later also failed to distinguish between
the groups.
Perceptual ratings of voice quality assessed by speech pathologists,
who were blinded to the type of therapy received, were also re-
ported. Breathiness (23.8 points; 95% CI -45.5 to -2.1; P = 0.03)
and hoarseness (17.2 points; 95% CI -34.3 to -0.1; P = 0.05)
showed greater improvements in the LSVT group than the RT
group.
The pitch (fundamental frequency) of the patient’s voice was mea-
sured objectively from monologue speech and reading a standard
passage; both methods failed to distinguish between the therapy
groups. Neither the initial post-treatment result nor the follow-up
results gave differences between the groups that were statistically
significant. Similarly, for the increase in the pitch of the patients’
voice reading a standard passage (the Rainbow Passage), the dif-
ferences were not statistically significant at either time point.
Communication aspects of QOLwere assessed in Ramig 1995 us-
ing the SIP communication and social interaction subsections. SIP
is a highly validated scale that uses a number of rated statements
to assess the severity of the impact of a disease on QOL. There was
no difference between the LSVT group and the RT group for these
outcome measures. Depression was assessed using the BDI. The
difference between the two groups was not statistically significant
immediately after therapy or at 12-month follow-up.
No assessment was made in Ramig 1995 of activities of daily living
and no economic analysis was performed.
Healy 2002
The number of syllables per minute for a sample of 22 sentences
(reading), a story telling and conversational speech was assessed by
a therapist as well as percentage of intelligible words in the sample
for the sentence reading and intelligibility rating (scale of one to
eight where eight is normal speech) for spontaneous conversational
speech. AnOro-motor assessment was carried out by the therapist,
for which movement of lips, tongue and soft palate and voice
quality are rated on a scale of one to eight where eight is normal.
This study group also included reported level of voluntary use of
devices outside of therapy sessions as an outcome measure, this
was self-rated by patients (scale of one to 10, where zero = never
used). Baseline data were not reported for this trial and the results
for the two different treatment schedule groups were amalgamated
for each intervention, precluding statistical analysis for this review.
Halpern 2007
TheDiagnostic Rhyme Test (DRT), which uses rhyming pairs dif-
fering only in their initial consonant, was used tomeasure intelligi-
bility before and after LSVT-ARTIC and LSVT-LOUD delivered
in Halpern 2007. Analysis of the recorded voice samples played
under three different noise conditions was carried out. LSVT-
LOUDgave a greater improvement than LSVT-ARTIC for babble
noise 12.5 points (95%CI -22.2 to -2.8; P = 0.01). No statistically
significant difference was recorded for the other two conditions (P
= 0.08 for shopping mall noise and P = 0.29 for no noise).
Those receiving LSVT-LOUD showed a greater improvement in
the loudness of reading the DRT word list difference of 5.0 dB
(95%CI -8.3 to -1.7; P = 0.003).
Halpern 2007 only reported measures of intelligibility and loud-
ness.
Lowit 2010
Lowit 2010 measured the intelligibility of two different speaking
modes using different methods. For monologue speech a nine-
point Likert scale showed no difference between the Altered Au-
ditory Feedback (AAF) and the Traditional Therapy (TT) groups
either immediately after therapy or six weeks later. The TT group
showed the greatest improvement for reading a passage as mea-
sured by the direct magnitude estimation (DME): the difference
for ratings immediately after therapy of 23.9 points (95% CI -
44.5 to -3.3; P = 0.02) was significant, however after six weeks the
difference was no longer statistically significant (P = 0.64).
Articulation rate was improved by 0.73 syllables/sec (95% CI -
1.33 to -0.13; P = 0.02) more in the AAF group than in the TT
group immediately after therapy. After six weeks the difference
between the two groups had increased slightly to 0.83 (95% CI -
1.43 to -0.23; P = 0.007).
Constantinescu 2011
Non-inferiority of online LSVT delivery compared with face-to-
face delivery was supported by non- significant differences in: ob-
jective measures of loudness of monologue speech (P = 1.0 for
the primary outcome measure), reading loudness (P = 0.8), dura-
tion of sustained phonation (P = 0.8) and maximum fundamental
frequency range (P = 0.9) taken from vocal glides. The only ob-
jective measure which showed a statistically significant difference
between the two delivery methods was sustained phonation, for
which the result was 10.0 dB (95% CI -12.8 to -7.2; P < 0.00001)
in favour of face-to-face LSVT.
Perceptual ratings of intelligibility were also reported for
Constantinescu 2011. The Assessment of Intelligibility of
Dysarthric Speech (ASSIDS) (Yorkston 1981), during which pa-
tients read 50 words and 22 sentences of increasing length which
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were randomised prior to the assessment, was used to analyse per-
centage sentence intelligibility, percentage word intelligibility, and
communication efficiency( CER). All parameters showed no sig-
nificant difference between the two methods of delivery for LSVT.
Monologue speech was assessed for perceptual voice ratings of
breathiness, roughness and overall articulatory precision (OAP).
No significant differences were reported for OAP and breathiness.
One of the few significant differences recorded was for roughness
which showed a difference between the mean changes from base-
line of 9.2 points (95% CI 1.5 to 16.9; P = 0.02) in favour of face-
to-face delivery. Patients were also asked to read a passage before
and after therapy, and their speech during this task was used to
obtain perceptual ratings of loudness level (P = 0.22), loudness
variability (P = 0.2) and pitch variability (P = 0.2). All outcome
measures for this task supported the non-inferiority of online de-
livery of LSVT as the differences between the mean changes of the
two groups were not statistically significant.
D I S C U S S I O N
Summary of main results
• Six randomised controlled trials were found comparing two
forms of speech and language therapy (159 patients). These trials
varied considerably in their methodology so the results could not
be combined by meta-analysis. One study examined the impact
of visual feedback on prosodic exercise techniques. Another
compared the Lee Silverman Voice Therapy (LSVT) technique
with respiration therapy. LSVT, in its original form (LSVT-
LOUD), was also compared with a modified version of itself
with cues and emphasis centred around articulation (LSVT-
ARTIC). A third trial also studied LSVT, comparing two
methods of delivering the treatment, to provide evidence for the
non-inferiority of online sessions compared with face-to-face
delivery. Two trials studying rate reduction techniques were
found. One of these trials compared an in-ear device giving
altered auditory feedback (AAF) with traditional rate reduction
behavioural therapy methods and the other compared an
alphabet board and a pacing board.
• LSVT improved loudness and monotonicity more than RT
in a variety of speaking modes in Ramig 1995. The result was
maintained for 12 months in the objective measures of
monologue and reading loudness and for 24 months in the
objective measures of sustained phonation loudness and
monotonicity. Patient and carer ratings of these outcomes failed
to distinguish between SLT methods but therapist ratings of
voice quality did show a significantly greater improvement in the
LSVT group.
• Halpern 2007 assessed patients for intelligibility and
loudness of speech pre- and immediately post-treatment but they
did not follow up the patients. Loudness improved more in the
LSVT-LOUD group than in the LSVT-ARTIC group.
Intelligibility of recorded speech was assessed three times with
different types of background noise overlaid onto it, only the
babble noise condition distinguished between the two groups
with LSVT-LOUD showing a greater improvement.
• The non-inferiority of online delivery of LSVT versus face-
to-face delivery of the therapy was supported by non-significant
differences in loudness, intelligibility and monotonicity in
Constantinescu 2011. Only pre- and immediately post-
treatment assessments were carried out in this trial.
• Despite improving the articulation rate of speakers by a
greater amount than traditional therapy (TT), AAF in-ear
devices were less successful than TT at improving the
intelligibility of speech.
• Limited evidence is presented in this review in favour of
LSVT (or LSVT-LOUD) over RT and LSVT-ARTIC and
supporting the non-inferiority of online delivery of LSVT
compared with traditional face-to-face delivery of the same
techniques. Larger trials are required to confirm these findings.
Overall completeness and applicability of
evidence
Outcome measures
It can be argued that intelligibility is the most critical outcome to
be measured in speech and language therapy trials. If this global
measure does not improve then it is irrelevant to the patient how
many other objective speech quality measures improve; they still
cannot be understood. All included trials assessed intelligibility
and almost all results were not statistically significant. The excep-
tion to this was the perceptual ratings of speech recordings over-
laid with babble noise (Halpern 2007) for which LSVT-LOUD
gave a greater improvement than LSVT-ARTIC (-12.5 points;
95% CI -22.2 to -2.8; P = 0.01). The non-inferiority of online
delivery of LSVT was supported by the intelligibility results of
Constantinescu 2011, who reported no statistically significant dif-
ference between the improvements in both acoustic and percep-
tual measures for this group and the face-to-face delivery group.
Parkinsonian speech is often characterised by a quiet voice. This
can exacerbate problems with intelligibility as listeners strain to
hear what is being said by the patient. All three trials for LSVT in-
cluded loudness as an outcome measure. Patients showed a greater
improvement from LSVT than alternative therapies with a dif-
ference for reading of 5.0 dB (95%CI -8.3 to -1.7; P = 0.003)
(Halpern 2007) and 5.5 dB (95% CI 3.4 to 7.7; P < 0.00001)
(Ramig 1995) and for monologue of 2.9 dB (95% CI 0.6 to 5.2;
P = 0.01) (Ramig 1995). Significant differences were recorded 12
months after therapy. Objective measures of monotonicity of a
monologue also favoured the LSVTmethod (0.47 semitones; 95%
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CI 0.01 to 0.93; P = 0.04). Constantinescu 2011 reported no sig-
nificant difference between online LSVT and face-to-face delivery
in reading and monologue loudness and monotonicity. Sustained
phonation loudness was one of the few outcome measures which
did not support the equivalence of the two methods of delivery
and this result was significant in favour of face-to-face delivery.
The prosodic abnormality score, which assesses volume, pitch,
tone, intonation, vocal quality (hoarse, tremor etc), rate and
rhythm, does not appear to have been independently assessed for
validity.
Adverse events were not reported by any of the trials included in
this review. Although the risk associated with speech and language
therapy is low, patients could be affected by vocal strain or abuse
during high effort exercises.
Quality of life (QOL) is recognised as a vital assessment inmodern
clinical trials so that the impact of a given therapy can be assessed
in the light of its perceived value to the patient. Only Ramig 1995
attempted to measure this using the communication and social
interaction subsections of SIP which failed to distinguish between
the two therapies studied.
Depression in trial participants could affect compliance and effec-
tiveness of therapy. In turn this outcome may be improved due to
time and attention or specific therapeutic techniques. It is impor-
tant to measure depression as a number of surveys (Karlsen 1999;
GPDS 2000; Zach 2004; Visser 2008) have found depression to
be themain contributor to a reduction in quality of life due to PD.
Ramig 1995 used the BDI to assess depression in their patients.
It did not detect any improvement in either of the two therapies
examined. On average, the patients assessed were not depressed as
defined by this scale.
Approximately 75% of patients with PD live with a partner, who
is usually of a similar age and may have disabilities of their own
(Lloyd 1999). The impact of caring for a person with PD can be
severe (O’Reilly 1996) and it would be hoped that an intervention
such as speech and language therapy could have a positive effect
on the carer’s life as well as the patient’s. Although Ramig 1995
did ask the carers for their assessment of the patient’s speech, they
did not ask what impact poor communication with the patient
had on their stress and strain levels and their QOL. All other trials
failed to assess carer outcomes.
No health economics analysis of speech and language therapy has
been performed which precludes an understanding of the eco-
nomic value of this therapy. The results of non-inferiority trials
such as Constantinescu 2011 contribute useful data to evaluate the
most cost effective modes of delivery in future health economics
analyses.
Speech and language therapy methodology
There is no consensus amongst therapists on which SLT method
to use or whether it should be a combination of methods. A recent
survey of speech and language therapists in the UK (Miller 2011),
showed a high proportion of patients with PD referred for SLT
receive only an assessment, advice and review service. When treat-
ment methods were employed, voice quality was most commonly
addressed with LSVT or other vocal loudness exercises and intelli-
gibility was treated with pacing/rate control exercises supported by
work on loudness. Psychosocial and language strategies were rarely
employed by the therapists surveyed despite these being flagged as
important reasons for referral. Over 75% of all therapists surveyed
wanted further training and over half of these specifically desired
training in LSVT techniques. As part of the same study, a survey
of SLT provision was carried out with patients with PD and their
carer’s (Miller 2011b). Of the 83 patients who had received any
treatment from a speech and language therapist, 56% had their
sessions in a local clinic or hospital outpatients setting and 37%
were visited in their own home. Median duration of therapy for
those treated was four weeks with 68% attending a single weekly
session, a further 22%, who were predominantly receiving LSVT,
had four or more therapy sessions per week. Most sessions (80%)
lasted between 30 to 60 minutes.
Speech and language therapy terminology
The terminology in this review has been aimed at a general clinical
audience unlike some of the trial reports. It is hoped that this
will improve understanding by non-SLT specialists. In an attempt
to make reading the original reports easier, we have included a
glossary in this review (Table 1: Glossary).
The same outcome measure was often labelled differently in dif-
ferent trials (e.g. volume and sound pressure level) which adds
further to the confusion. It was also difficult for a non-specialist
to determine the value of any given change in the vocal charac-
teristics measured in these trials. Care should be taken when writ-
ing reports of speech therapy that an association is made with the
direction and size of change in a given outcome measure and its
impact on the communication ability of the patient.
Quality of the evidence
The methodological quality of the trials and the standard of
the reporting was mixed, but Scott 1983 and Ramig 1995
were published before the CONSORT guidelines were published
(CONSORT 1996). The trials used insufficient numbers of pa-
tients to avoid making false positive or false negative conclusions
and to reduce the possibility of selection bias. It can be argued that
the primary outcome of interest in SLT trials should be improved
intelligibility which was an outcome in all included trials.
The trials included in this review used a variety of randomisation
methods, but all omitted to report whether concealment of allo-
cation had been achieved, leaving the risk of selection bias unclear
or high in all cases. It is vital that eligibility criteria, including type
and severity of PD as well as co-existing conditions, are stated so
that the population treated during the trial is well defined. This
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enables treating physicians to assess the results of the trials for rel-
evance to their patients.
There is no difference between the prevalence of PD in men and
that in women (Tanner 1996). Only 28% of the patients enrolled
into the trials were female and so the trial groups were not truly
representative of the general PD population.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Considering the small number of patients examined and the
methodological flaws in the studies, it is unsafe to draw any con-
clusions regarding the efficacy of one form of speech and language
therapy in preference over another for the treatment of speech
problems in PD.
Implications for research
To obtain proof of the efficacy of speech and language therapy for
speech disorders in patients with PD, large randomised placebo-
controlled trials are required. After this, large RCTs are needed
to demonstrate the most effective form of SLT to treat speech
disorders in PD. All of these trials should use a rigorous method
of randomisation and adequate concealment of allocation. Data
should be analysed on an intention-to-treat basis. Trials should
be reported according to CONSORT guidelines (CONSORT
1996).The methodological shortcomings highlighted in this re-
view have a significant bearing on the conduct of future speech
and language therapy trials in Parkinson’s disease.
• Firm diagnostic criteria should be used (e.g. UK Parkinson’s
Disease Brain Bank Criteria) (Gibb 1988).
• Inclusion and exclusion criteria should be clear and trials
should aim to enrol uniform cohorts of patients with PD.
• Investigators should clarify at what stage of the disease
speech and language therapy is being evaluated.
• Trials must have sufficient numbers of patients to avoid
false negative or false positive conclusions.
• Trials must include a clear description of the two
therapeutic interventions.
• The patients should be followed for at least six months after
treatment to assess the duration of any benefit from the SLT
intervention.
• Regardless of the scale used, trials should report whether
scores on impairment and disability refer to the ’on’ or ’off ’
phase.
• Suitable clinimetrically sound outcome measures should be
chosen so that the efficacy and effectiveness of SLT can be
assessed and an economic analysis performed. Outcomes which
have meaning to patients should be used wherever possible since
they need to know the value of SLT in practical terms.
• The data must be analysed on an intention-to-treat basis
and the change in an outcome measure must be compared
statistically across the two therapy groups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Constantinescu 2011
Methods Parallel group non-inferiority trial design. Based upon their dysarthria severity classification
the participants were stratified and then assigned to a treatment group using a computerised
random number generator. The primary investigator generated the random number and as-
signed the participants in order of recruitment to the study, concealment of allocation was not
confirmed in the published information. Data from the first 8 participants recruited to the
study were used to carry out a power calculation and the resulting target, plus an additional
10% to allow for some drop-out from the study, was met. It is assumed that data would have
been analysed on an intention-to-treat basis if any patients had withdrawn from the study,
although this was not stated. Treatment was administered in an outpatient setting, in 4 sessions
per week for 4 weeks with each session lasting 1 hour. Assessments were carried out pre- and
post-treatment and assessors were blinded to treatment group
Participants 17 participants in novel (online delivery of LSVT) and 17 in standard (face-to-face delivery
of LSVT). No drop-outs were mentioned in the published material. Patients mean age 70.65
(online), 69.59 (face-to-face); male/female 14/3 (online), 13/4 (face-to-face); Hoehn and Yahr
1.59 (online), 1.53 (face-to-face); duration of condition/years 5.39 (online), 6.88 (face-to-
face). Inclusion criteria: presence of hypokinetic dysarthria (mild to severe) with PD impacting
on communication; a videolaryngoscopic evaluation of the vocal fold structure and movement
consistent with PD; ability when guided to increase loudness; and a consistent drug regimen
for PD. Exclusion criteria: speech and/or language difficulties unrelated to PD; an additional
co-existing neurological disorder; respiratory difficulties inconsistent with PD; cognitive diffi-
culties resulting in the inability to provide informed consent; a severe uncorrected visual and/
or auditory disturbance; a history of alcohol abuse; and participation in the LSVT within 12
months of this study
Interventions Novel treatment: LSVT, a high effort intensive treatment increasing vocal loudness through
increasing vocal fold adduction, thinking loud and increased respiratory effort, delivered via
PC-based video conferencing between patient and speech-language pathologist in a separate
room. Standard treatment: Same LSVT methods delivered face-to-face by speech-language
pathologist
Outcomes Primary: Sound pressure levels
Secondary (acoustic): Phonation time, maximum fundamental frequency range
Secondary (perceptual): Breathiness, roughness, overall articulatory precision, loudness level,
pitch loudness and variation, participant satisfaction
Notes Participant satisfaction questionnaire only completed by novel arm group so data cannot be
used in this review. Subgroup analysis by dysarthria severity was carried out
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Low risk Inclusion criteria stated
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Constantinescu 2011 (Continued)
Randomisation method Low risk Randomised by computer random number
generator
Adequate concealment of allocation Unclear risk Concealment of allocation not stated
Similar at baseline Low risk Groups similar in age, duration of condition,
severity of condition and male/female ratio
Withdrawals > 10% Low risk No withdrawals
Missing values > 10% Low risk No missing data
Cointerventions constant Unclear risk Consistent drug regimen stated as inclusion
criteria but no report on whether this was
maintained throughout trial period
Credible placebo Low risk Equal time spent training each group
Blinded assessors Low risk Patients instructed not to divulge their treat-
ment allocation to assessors
Halpern 2007
Methods Parallel group trial design. The participants were assigned to a treatment group using a com-
puterised randomisation method. It is assumed that data would have been analysed on an
intention-to-treat basis if any patients had withdrawn from the study, although this was not
stated. Treatment was administered in 4 sessions per week for 4 weeks with each session lasting
50 minutes. Assessments were carried out pre- and post-treatment
Participants 8 participants in novel (Articulation-focused LSVT) and 10 in standard (Loudness-focused
LSVT). No drop-outs were mentioned in the published material. Patients mean age 70.5
(LSVT Artic), 66.1 (LSVT LOUD); male/female 6/2 (LSVT Artic), 7/3 (LSVT LOUD);
Hoehn and Yahr (stage on meds) score 2.2 (LSVT Artic) and 2.2 (LSVT LOUD); duration
of condition was not assessed. No inclusion or exclusion criteria stated
Interventions Novel Therapy: LSVTArtic, following same general principles as LSVT as described for Ramig
1995 but with focus on articulation and cue used is ENUNCIATE. Standard therapy, LSVT
Loud, as described for Ramig 1995 with original LOUD cue used.
Outcomes Speech intelligibility measured using DRT for no noise, shopping mall noise and babble noise
conditions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Halpern 2007 (Continued)
Specified eligibility criteria High risk Criteria not stated
Randomisation method Low risk Randomised by computer random number
generator
Adequate concealment of allocation Unclear risk Concealment of allocation not stated
Similar at baseline Unclear risk Groups similar in age, severity of condition
and male/female ratio
Withdrawals > 10% Low risk No withdrawals
Missing values > 10% Low risk No missing data
Cointerventions constant Low risk Stable drug regimen confirmed through cor-
respondence with author
Credible placebo Low risk Same time and attention for both groups
Blinded assessors Low risk Blinding of assessors confirmed through cor-
respondence with author
Healy 2002
Methods Parallel group trial design. The participants were assigned to a treatment group using a sealed
envelope randomisation method. It is unreported whether data were analysed on an intention-
to-treat basis or if any patients had withdrawn from the study. Treatment was administered in
a single hour long session or in 6 sessions each lasting an hour over 6 weeks. Assessments were
carried out pre- and post-treatment and at 1 week, 6 weeks and 6 months after treatment
Participants Baseline characteristics were not stated for the different groups. Inclusion criteria: diagnosis
of PD, faster than normal speech rate/evidence of palilalia with or without other dysarthric
features, able to cope with individual therapy sessions and consent to take part on this basis.
Exclusion criteria: score of 9 or below on Middlesex Elderly Assessment of Mental State
(MEAMS) (Golding 1989) indicating cognitive impairment, unclear diagnosis of PD, recent
or anticipated change in Parkinsonian-related medication, previous exposure to pacing therapy
techniques used in study, Parkinson speakers with normal/slow speech rates, inability to cope
with individual therapy sessions lasting up to two hours e.g. due to poor concentration or
excessive fatigue
Interventions Therapy 1, alphabet board. Speaker points to the initial letter of each word spoken on the
board this task is intended to control rate of speech. Therapy 2, Pacing board. Wooden ruler
with series of raised divisions at 30 mm intervals. Speaker is required to place their finger in
each section as they speak each word. Tactile feedback is intended to help control speech rate
Outcomes Sentence rate and intelligibility (assessment of intelligibility of dysarthric speech using 22
sentences)
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Healy 2002 (Continued)
Narrative rate
Spontaneous speech rate and intelligibility from conversation
Oro-motor assessment, Frenchay dysarthria assessment
Reported use of devices
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Low risk Inclusion and exclusion criteria stated
Randomisation method High risk Sealed envelope randomisation method
Adequate concealment of allocation High risk Sealed envelope randomisation method
Similar at baseline Unclear risk Baseline characteristics of groups not stated
Withdrawals > 10% Unclear risk N numbers for time points not stated
Missing values > 10% Unclear risk Means given with N numbers for time points
not stated
Cointerventions constant Unclear risk No report of whether drug regimens were con-
stant throughout trial
Credible placebo Low risk Matching treatment schedules for each tech-
nique
Blinded assessors Low risk Audiotapes analysed by a qualified speech
and language therapist blinded to participants
group
Lowit 2010
Methods Cross-over trial, data from first treatment session obtained through correspondence with au-
thor. The participants were randomly assigned to a treatment group using alternate allocation
by order of entry into study. Data have been analysed on as per protocol basis. Treatment
was administered in the patients homes, in 1 session per week for 4 weeks with each session
lasting 50 - 60 minutes. Assessments were carried out pre- and post-treatment and assessors
were blinded to treatment group, time of assessment and feedback preference for in-ear device
Participants 5 participants in novel (altered auditory feedback (AAF) in-ear device) and 5 in standard
(traditional rate reduction therapy (TT)). 1 patient was unable to participate in post treatment
analysis of articulation rate. Patients mean age 62.6 (AAF), 63.0 (TT); male/female 4/1 (AAF)
, 2/3 (TT); Hoehn and Yahr 1.8 (AAF), 3.3 (TT); duration of condition was not assessed.
Inclusion criteria: Idiopathic PD and a speech impairment severe enough to warrant treatment.
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Lowit 2010 (Continued)
Exclusion criteria: Presence of significant dementia, history of deep brain stimulation or speech
and language therapy for dysarthria symptoms during the last 12 months, presence of speech
and language problems other than those caused by PD
Interventions Novel therapy, AAF is an in-ear device worn by patients which disrupts the normal auditory
feedback loop causing a slowing in the rate of speech. Participants used delayed auditory
feedback (DAF) and frequency shifted feedback (FSF) and were encouraged to choose their
preferred setting as part of this trial. Standard therapy, TTfocused on identifying the most
suitable strategy for reducing speech rate e.g. increasing pauses or stretching out articulation
Outcomes Articulation rate from reading a passage
Intelligibility from reading a passage and a monologue task
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Low risk Inclusion criteria stated
Randomisation method High risk Quasi-random method, alternate allocation
Adequate concealment of allocation High risk Quasi-random method, alternate allocation
Similar at baseline High risk Groups differ in mean stage of disease (Hoehn
and Yahr)
Withdrawals > 10% Low risk 1 drop-out from 10 recruited to trial
Missing values > 10% Low risk 1 drop-out from 10 recruited to trial
Cointerventions constant High risk Two patients had to change their medication
during treatment
Credible placebo High risk In-ear device compared with behavioural ex-
ercises
Blinded assessors Low risk Experimenter who processed rate data and
judges who rated intelligibility were blinded
to treatment group
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Ramig 1995
Methods Parallel group design. Randomised by number picked out of a hat, so no concealment of
allocation. Analysed on a per protocol basis. Treated as outpatients for 16 hours over 1 month.
Assessed at baseline, immediately after treatment, 6, 12, 24 and 48 months later. Assessors
were blinded
Participants 26 patients in novel LSVT) group and 19 in standard (respiration therapy) group. After two
years, 5 drop-outs in LSVT group and 7 in respiration group. Patients mean age 63.5 (LSVT),
65.6 (respiration); male/female 21/5 (LSVT), 12/7 (respiration); Hoehn and Yahr 2.7 (LSVT)
, 2.3 (respiration); duration of condition/years 8.3 (LSVT), 5.9 (respiration). No inclusion
criteria stated. Exclusion criteria: not idiopathic PD, having laryngeal pathology
Interventions Novel treatment: LSVT, a high effort intensive treatment increasing vocal loudness through
increasing vocal fold adduction, thinking loud and increased respiratory effort.
Standard treatment: Respiration therapy, aimed at increased respiratory muscle activity. Visual
feedback was provided. Drugs stable during therapy period, and patients were ’optimally
medicated’ throughout follow-up period
Outcomes Fundamental frequency
Sound pressure levels
Intelligibility
Beck Depression Index
Sickness Impact Profile - (communication and social interaction)
UPDRS
Hoehn & Yahr
etc
All measured in ’on’ phase.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria Low risk Exclusion criteria stated
Randomisation method High risk Numbers pulled out of a hat
Adequate concealment of allocation High risk Numbers pulled out of a hat randomisation
method
Similar at baseline Low risk Groups similar in age, duration of condition,
severity of condition and male/female ratio
Withdrawals > 10% Unclear risk Patient numbers decreased in subsequent pub-
lications but it is unclear whether these are
subgroup studies, withdrawals or missing val-
ues
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Ramig 1995 (Continued)
Missing values > 10% Unclear risk Patient numbers decreased in subsequent pub-
lications but it is unclear whether these are
subgroup studies, withdrawals or missing val-
ues
Cointerventions constant Low risk Stable drug regimen throughout treatment pe-
riod, optimally medicated for follow-up
Credible placebo Low risk Same time and attention for both groups
Blinded assessors Unclear risk Perceptual measures were rated blindly
Scott 1983
Methods Parallel group design. Randomised using random number tables. Allocation was concealed
from therapist. Data analysed on a per protocol basis. Treated at home for 10 hours over
2 weeks. Assessed at baseline, immediately after therapy and 3 months later. The prosodic
abnormality score was scored by an unblinded and a blinded assessor and the mean taken. The
remainder of the outcomes were assessed blinded
Participants 13 per arm of study. After 3 months, 3 drop-outs in novel (visual stimulation) group, 1 drop-
out in standard (prosodic exercises) group. Patients mean age 66 in both arms; male/female
7/6 (visual), 11/2 (prosodic); duration of condition/years 13 (visual), 10 (prosodic); Hoehn
and Yahr score was not assessed. Inclusion criteria: patients with PD with a speech disorder.
Exclusion criteria: Subjectively slight communication difficulty, evidence of intellectual im-
pairment, history of stroke or other disorder likely to affect speech, significant impairment of
hearing, drug therapy likely to vary, unlikely to co-operate in trial
Interventions Novel treatment: Prosodic exercises with visual stimulation (Vocalite). The exercises aimed
to improve prosodic abnormality by increasing the patients awareness of the problem and
emphasising the importance of volume and intonation.
Standard treatment: Prosodic exercises alone.
Drug therapy was constant.
Outcomes Prosodic abnormality score
Intelligibility rating
Visual analogue score of intelligibility
Notes After 2 weeks of standard therapy this group had a further week of prosodic exercises with the
visual stimulation of a Vocalite. Therefore, data after the first 2 week period were not used in
this review
Risk of bias
Bias Authors’ judgement Support for judgement
Specified eligibility criteria High risk Inclusion criteria stated
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Scott 1983 (Continued)
Randomisation method Unclear risk Random number tables
Adequate concealment of allocation Unclear risk Concealment of allocation not stated
Similar at baseline Unclear risk Groups similar in age and duration of condi-
tion,male/female ratio differs between groups,
stage of disease not reported
Withdrawals > 10% Low risk Withdrawals reach high risk level for 3-month
follow-up data not included in this review
Missing values > 10% High risk Missing data reached high risk level for 3-
month follow-up data not included in this re-
view
Cointerventions constant Unclear risk Stable drug regimen
Credible placebo Low risk Same time and attention for both groups
Blinded assessors Low risk Prosodic abnormality score was scored by an
unblinded and a blinded assessor and themean
taken. Intelligibility outcomes were assessed
blinded
AAF: altered auditory feedback
DAF: delayed auditory feedback
DRT: Diagnostic Rhyme Test
FSF: frequency shifted feedback
LSVT: Lee Silverman Voice Treatment
MEAMS: Middlesex Elderly Assessment of Mental State
PD: Parkinson’s disease
TT: traditional rate reduction therapy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 2002 This RCT examined the motor learning principles involved in the acquisition and retention of novel speech skills.
Intervention did not aim to improve everyday speech of participants, but studied the ability of the patients with
PD to learn to speak at a target rate. Outcomes were not relevant to this review question
de Swart 2003 This trial investigated the effects of Pitch Limiting Voice Treatment (PVLT), “speak loud and low” compared with
LSVT, “think loud, think shout”. Both treatments were aimed to increase loudness but the novel PLVT therapy
aimed to do this without raising the vocal pitch and laryngeal muscle tension. The patients withPD in this trial
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(Continued)
were not randomised, all took part in both types of therapy
Pacchetti 2000 This RCT studied the effects of music therapy versus physical therapy on the motor and emotional health of
people with PD, by combining movement and stimulation of different sensory pathways. No speech outcomes were
investigated
Tindall 2009 This trial studies voice treatment delivered via a videophone and compares to historical data for traditional delivery.
The study is therefore not randomised or adequately controlled
LSVT: Lee Silverman Voice Treatment
PD: Parkinson’s disease
PVLT: Pitch Limiting Voice Treatment
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. LSVT versus high respiratory effort treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patient assessed loudness 1 45 Mean Difference (IV, Fixed, 95% CI) 3.30 [-10.71, 17.31]
2 Carer assessed loudness 1 20 Mean Difference (IV, Fixed, 95% CI) 1.60 [-19.89, 23.09]
3 Patient assessed monotonicity 1 45 Mean Difference (IV, Fixed, 95% CI) 8.7 [-4.56, 21.96]
4 Carer assessed monotonicity 1 20 Mean Difference (IV, Fixed, 95% CI) 3.10 [-19.03, 25.23]
5 Patient assessed intelligibility 1 52 Mean Difference (IV, Fixed, 95% CI) 3.60 [-6.98, 14.18]
6 Carer assessed intelligibility 1 20 Mean Difference (IV, Fixed, 95% CI) 10.70 [-7.21, 28.61]
7 SPL Reading 1 147 Mean Difference (IV, Fixed, 95% CI) 3.62 [2.36, 4.89]
7.1 Pre/Post 1 45 Mean Difference (IV, Fixed, 95% CI) 5.54 [3.35, 7.73]
7.2 Pre/6 months 1 35 Mean Difference (IV, Fixed, 95% CI) 2.4 [-0.05, 4.85]
7.3 Pre/12 months 1 35 Mean Difference (IV, Fixed, 95% CI) 2.8 [0.24, 5.36]
7.4 Pre/24 months 1 32 Mean Difference (IV, Fixed, 95% CI) 2.90 [-0.31, 6.11]
8 SPL Monologue 1 89 Mean Difference (IV, Fixed, 95% CI) 2.49 [1.22, 3.76]
8.1 Pre/Post 1 29 Mean Difference (IV, Fixed, 95% CI) 2.9 [0.63, 5.17]
8.2 Pre/6 months 1 21 Mean Difference (IV, Fixed, 95% CI) 1.6 [-0.71, 3.91]
8.3 Pre/12 months 1 21 Mean Difference (IV, Fixed, 95% CI) 3.8 [1.21, 6.39]
8.4 Pre/24 months 1 18 Mean Difference (IV, Fixed, 95% CI) 1.30 [-2.01, 4.61]
9 Fundamental frequency reading 1 109 Mean Difference (IV, Fixed, 95% CI) 3.96 [-3.66, 11.58]
9.1 Pre/Post 1 43 Mean Difference (IV, Fixed, 95% CI) 4.90 [-7.37, 17.17]
9.2 Pre/6 months 1 33 Mean Difference (IV, Fixed, 95% CI) 3.80 [-9.63, 17.23]
9.3 Pre/12 months 1 33 Mean Difference (IV, Fixed, 95% CI) 2.90 [-11.20, 17.00]
10 Frequency variability
monologue
1 93 Mean Difference (IV, Fixed, 95% CI) 0.57 [0.28, 0.85]
10.1 Pre/post 1 29 Mean Difference (IV, Fixed, 95% CI) 0.47 [0.01, 0.93]
10.2 Pre/6 months 1 22 Mean Difference (IV, Fixed, 95% CI) 0.43 [-0.14, 1.00]
10.3 Pre/12 months 1 22 Mean Difference (IV, Fixed, 95% CI) 0.75 [0.13, 1.37]
10.4 Pre/24 months 1 20 Mean Difference (IV, Fixed, 95% CI) 0.77 [0.06, 1.48]
11 Frequency variability reading 1 141 Mean Difference (IV, Fixed, 95% CI) 0.24 [0.08, 0.41]
11.1 Pre/post 1 43 Mean Difference (IV, Fixed, 95% CI) 0.27 [-0.03, 0.57]
11.2 Pre/6 months 1 33 Mean Difference (IV, Fixed, 95% CI) 0.18 [-0.16, 0.52]
11.3 Pre/12 months 1 33 Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.08, 0.66]
11.4 Pre/24 months 1 32 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.12, 0.58]
12 Fundamental frequency
monologue
1 73 Mean Difference (IV, Fixed, 95% CI) 3.28 [-4.73, 11.30]
12.1 Pre/post 1 29 Mean Difference (IV, Fixed, 95% CI) 8.2 [-5.35, 21.75]
12.2 Pre/6 months 1 22 Mean Difference (IV, Fixed, 95% CI) 4.30 [-9.60, 18.20]
12.3 Pre/12 months 1 22 Mean Difference (IV, Fixed, 95% CI) -3.2 [-17.43, 11.03]
13 BDI self rating of depression 1 60 Mean Difference (IV, Fixed, 95% CI) -0.79 [-3.82, 2.23]
13.1 Pre/post 1 35 Mean Difference (IV, Fixed, 95% CI) -1.1 [-4.72, 2.52]
13.2 Pre/12 months 1 25 Mean Difference (IV, Fixed, 95% CI) -0.07 [-5.60, 5.46]
14 SIP Communication 1 59 Mean Difference (IV, Fixed, 95% CI) -13.88 [-25.80, -1.
96]
14.1 Pre/post 1 35 Mean Difference (IV, Fixed, 95% CI) -14.5 [-29.37, 0.37]
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14.2 Pre/12 months 1 24 Mean Difference (IV, Fixed, 95% CI) -12.76 [-32.71, 7.
19]
15 SIP social interaction 1 59 Mean Difference (IV, Fixed, 95% CI) -1.35 [-6.98, 4.28]
15.1 Pre/post 1 35 Mean Difference (IV, Fixed, 95% CI) -0.40 [-6.80, 6.00]
15.2 Pre/12 months 1 24 Mean Difference (IV, Fixed, 95% CI) -4.6 [-16.42, 7.22]
16 Hoarseness 1 20 Mean Difference (IV, Fixed, 95% CI) -17.20 [-34.29, -0.
11]
17 Breathiness 1 20 Mean Difference (IV, Fixed, 95% CI) -23.8 [-45.50, -2.10]
18 SPL sustained phonation 1 148 Mean Difference (IV, Fixed, 95% CI) 11.12 [9.43, 12.81]
18.1 Pre/post 1 45 Mean Difference (IV, Fixed, 95% CI) 14.3 [11.52, 17.08]
18.2 Pre/6 months 1 35 Mean Difference (IV, Fixed, 95% CI) 10.6 [6.98, 14.22]
18.3 Pre/12 months 1 35 Mean Difference (IV, Fixed, 95% CI) 9.5 [6.04, 12.96]
18.4 Pre/24 months 1 33 Mean Difference (IV, Fixed, 95% CI) 7.3 [3.29, 11.31]
Comparison 2. LSVT Artic versus LSVT Loud
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SPL Reading Pre/Post 1 18 Mean Difference (IV, Fixed, 95% CI) -5.03 [-8.32, -1.74]
2 DRT Score Babble Noise
Pre/Post
1 18 Mean Difference (IV, Fixed, 95% CI) -12.46 [-22.15, -2.
77]
3 DRT Score Shopping Mall
Noise Pre/Post
1 18 Mean Difference (IV, Fixed, 95% CI) -11.64 [-24.73, 1.
45]
4 DRT Score No Noise Pre/Post 1 18 Mean Difference (IV, Fixed, 95% CI) -2.06 [-5.90, 1.78]
Comparison 3. Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Speech Rate Reading Pre/Post 1 9 Mean Difference (IV, Fixed, 95% CI) -0.73 [-1.33, -0.13]
2 Speech Rate Reading Pre/6Week
Follow-up
1 9 Mean Difference (IV, Fixed, 95% CI) -0.83 [-1.43, -0.23]
3 Intelligibility Reading Pre/Post 1 10 Mean Difference (IV, Fixed, 95% CI) -23.89 [-44.46, -3.
32]
4 Intelligibility Reading Pre/6
Week Follow-up
1 10 Mean Difference (IV, Fixed, 95% CI) -5.48 [-28.49, 17.
53]
5 Intelligibility Monologue
Pre/Post
1 10 Mean Difference (IV, Fixed, 95% CI) 0.10 [-2.48, 2.68]
6 Intelligibility Monologue Pre/6
Week Follow-up
1 10 Mean Difference (IV, Fixed, 95% CI) 0.04 [-2.06, 2.14]
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Comparison 4. Online LSVT versus face-to-face LSVT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SPL Monologue 1 34 Mean Difference (IV, Fixed, 95% CI) -0.01 [-1.89, 1.87]
2 SPL sustained vowel phonation 1 34 Mean Difference (IV, Fixed, 95% CI) -10.01 [-12.85, -7.
17]
3 SPL reading 1 34 Mean Difference (IV, Fixed, 95% CI) 0.25 [-1.74, 2.24]
4 Duration of phonation 1 34 Mean Difference (IV, Fixed, 95% CI) 0.37 [-2.64, 3.38]
5 Max fundamental frequency
range
1 34 Mean Difference (IV, Fixed, 95% CI) 0.39 [-4.12, 4.90]
6 Breathiness 1 34 Mean Difference (IV, Fixed, 95% CI) 5.53 [-3.44, 14.50]
7 Roughness 1 34 Mean Difference (IV, Fixed, 95% CI) 9.2 [1.49, 16.91]
8 Loudness level 1 34 Mean Difference (IV, Fixed, 95% CI) -7.74 [-20.23, 4.75]
9 Loudness variability 1 34 Mean Difference (IV, Fixed, 95% CI) 5.38 [-2.85, 13.61]
10 Pitch variability 1 34 Mean Difference (IV, Fixed, 95% CI) 6.49 [-2.67, 15.65]
11 Overall articulatory precision 1 34 Mean Difference (IV, Fixed, 95% CI) 9.14 [-0.66, 18.94]
12 Overall speech intelligibility in
conversation
1 34 Mean Difference (IV, Fixed, 95% CI) -9.08 [-20.74, 2.58]
13 Percentage word intelligibility 1 34 Mean Difference (IV, Fixed, 95% CI) -2.13 [-7.84, 3.58]
14 Percentage sentence
intelligibility
1 34 Mean Difference (IV, Fixed, 95% CI) -1.37 [-3.98, 1.24]
15 Communication efficiency
ratio
1 34 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.15, 0.15]
Analysis 1.1. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 1 Patient assessed
loudness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 1 Patient assessed loudness
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 26 17.3 (20.6) 19 14 (25.7) 100.0 % 3.30 [ -10.71, 17.31 ]
Total (95% CI) 26 19 100.0 % 3.30 [ -10.71, 17.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours RET Favours LSVT
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Analysis 1.2. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 2 Carer assessed
loudness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 2 Carer assessed loudness
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 12 15 (20.9) 8 13.4 (25.9) 100.0 % 1.60 [ -19.89, 23.09 ]
Total (95% CI) 12 8 100.0 % 1.60 [ -19.89, 23.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.3. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 3 Patient assessed
monotonicity.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 3 Patient assessed monotonicity
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 26 19.7 (20.2) 19 11 (23.9) 100.0 % 8.70 [ -4.56, 21.96 ]
Total (95% CI) 26 19 100.0 % 8.70 [ -4.56, 21.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.4. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 4 Carer assessed
monotonicity.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 4 Carer assessed monotonicity
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 12 14.1 (24.5) 8 11 (24.9) 100.0 % 3.10 [ -19.03, 25.23 ]
Total (95% CI) 12 8 100.0 % 3.10 [ -19.03, 25.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.5. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 5 Patient assessed
intelligibility.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 5 Patient assessed intelligibility
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 26 14 (18.8) 26 10.4 (20.1) 100.0 % 3.60 [ -6.98, 14.18 ]
Total (95% CI) 26 26 100.0 % 3.60 [ -6.98, 14.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.6. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 6 Carer assessed
intelligibility.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 6 Carer assessed intelligibility
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 12 17.8 (18.8) 8 7.1 (20.8) 100.0 % 10.70 [ -7.21, 28.61 ]
Total (95% CI) 12 8 100.0 % 10.70 [ -7.21, 28.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.7. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 7 SPL Reading.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 7 SPL Reading
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/Post
Ramig 1995 26 8.04 (4.5) 19 2.5 (3) 33.3 % 5.54 [ 3.35, 7.73 ]
Subtotal (95% CI) 26 19 33.3 % 5.54 [ 3.35, 7.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.95 (P < 0.00001)
2 Pre/6 months
Ramig 1995 22 3.9 (3.7) 13 1.5 (3.5) 26.6 % 2.40 [ -0.05, 4.85 ]
Subtotal (95% CI) 22 13 26.6 % 2.40 [ -0.05, 4.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
3 Pre/12 months
Ramig 1995 22 3 (3.6) 13 0.2 (3.8) 24.5 % 2.80 [ 0.24, 5.36 ]
Subtotal (95% CI) 22 13 24.5 % 2.80 [ 0.24, 5.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
4 Pre/24 months
Ramig 1995 21 3.6 (3.5) 11 0.7 (4.8) 15.6 % 2.90 [ -0.31, 6.11 ]
Subtotal (95% CI) 21 11 15.6 % 2.90 [ -0.31, 6.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Total (95% CI) 91 56 100.0 % 3.62 [ 2.36, 4.89 ]
Heterogeneity: Chi2 = 4.48, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 5.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.48, df = 3 (P = 0.21), I2 =33%
-100 -50 0 50 100
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Analysis 1.8. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 8 SPL Monologue.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 8 SPL Monologue
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/Post
Ramig 1995 16 4.5 (3.8) 13 1.6 (2.4) 31.1 % 2.90 [ 0.63, 5.17 ]
Subtotal (95% CI) 16 13 31.1 % 2.90 [ 0.63, 5.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
2 Pre/6 months
Ramig 1995 13 0.8 (2.8) 8 -0.8 (2.5) 30.2 % 1.60 [ -0.71, 3.91 ]
Subtotal (95% CI) 13 8 30.2 % 1.60 [ -0.71, 3.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
3 Pre/12 months
Ramig 1995 13 1.9 (3) 8 -1.9 (2.9) 24.0 % 3.80 [ 1.21, 6.39 ]
Subtotal (95% CI) 13 8 24.0 % 3.80 [ 1.21, 6.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
4 Pre/24 months
Ramig 1995 12 2.3 (2.3) 6 1 (3.8) 14.7 % 1.30 [ -2.01, 4.61 ]
Subtotal (95% CI) 12 6 14.7 % 1.30 [ -2.01, 4.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 54 35 100.0 % 2.49 [ 1.22, 3.76 ]
Heterogeneity: Chi2 = 2.18, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Chi2 = 2.18, df = 3 (P = 0.54), I2 =0.0%
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Analysis 1.9. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 9 Fundamental
frequency reading.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 9 Fundamental frequency reading
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/Post
Ramig 1995 26 16 (21.6) 17 11.1 (19) 38.6 % 4.90 [ -7.37, 17.17 ]
Subtotal (95% CI) 26 17 38.6 % 4.90 [ -7.37, 17.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 Pre/6 months
Ramig 1995 21 11.8 (24) 12 8 (15.3) 32.2 % 3.80 [ -9.63, 17.23 ]
Subtotal (95% CI) 21 12 32.2 % 3.80 [ -9.63, 17.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
3 Pre/12 months
Ramig 1995 21 9 (24.7) 12 6.1 (16.5) 29.2 % 2.90 [ -11.20, 17.00 ]
Subtotal (95% CI) 21 12 29.2 % 2.90 [ -11.20, 17.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 68 41 100.0 % 3.96 [ -3.66, 11.58 ]
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
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Analysis 1.10. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 10 Frequency
variability monologue.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 10 Frequency variability monologue
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 16 0.29 (0.51) 13 -0.18 (0.7) 38.6 % 0.47 [ 0.01, 0.93 ]
Subtotal (95% CI) 16 13 38.6 % 0.47 [ 0.01, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
2 Pre/6 months
Ramig 1995 13 0.33 (0.56) 9 -0.1 (0.73) 25.0 % 0.43 [ -0.14, 1.00 ]
Subtotal (95% CI) 13 9 25.0 % 0.43 [ -0.14, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
3 Pre/12 months
Ramig 1995 13 0.56 (0.79) 9 -0.19 (0.69) 20.6 % 0.75 [ 0.13, 1.37 ]
Subtotal (95% CI) 13 9 20.6 % 0.75 [ 0.13, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
4 Pre/24 months
Ramig 1995 11 0.65 (0.91) 9 -0.12 (0.71) 15.8 % 0.77 [ 0.06, 1.48 ]
Subtotal (95% CI) 11 9 15.8 % 0.77 [ 0.06, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.034)
Total (95% CI) 53 40 100.0 % 0.57 [ 0.28, 0.85 ]
Heterogeneity: Chi2 = 1.05, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000089)
Test for subgroup differences: Chi2 = 1.05, df = 3 (P = 0.79), I2 =0.0%
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Analysis 1.11. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 11 Frequency
variability reading.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 11 Frequency variability reading
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 26 0.56 (0.61) 17 0.29 (0.38) 32.0 % 0.27 [ -0.03, 0.57 ]
Subtotal (95% CI) 26 17 32.0 % 0.27 [ -0.03, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
2 Pre/6 months
Ramig 1995 21 0.42 (0.59) 12 0.24 (0.39) 25.0 % 0.18 [ -0.16, 0.52 ]
Subtotal (95% CI) 21 12 25.0 % 0.18 [ -0.16, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 Pre/12 months
Ramig 1995 21 0.43 (0.71) 12 0.14 (0.37) 20.6 % 0.29 [ -0.08, 0.66 ]
Subtotal (95% CI) 21 12 20.6 % 0.29 [ -0.08, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
4 Pre/24 months
Ramig 1995 20 0.39 (0.6) 12 0.16 (0.42) 22.3 % 0.23 [ -0.12, 0.58 ]
Subtotal (95% CI) 20 12 22.3 % 0.23 [ -0.12, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 88 53 100.0 % 0.24 [ 0.08, 0.41 ]
Heterogeneity: Chi2 = 0.24, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 0.24, df = 3 (P = 0.97), I2 =0.0%
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Analysis 1.12. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 12 Fundamental
frequency monologue.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 12 Fundamental frequency monologue
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 16 8.6 (15.9) 13 0.4 (20.4) 35.0 % 8.20 [ -5.35, 21.75 ]
Subtotal (95% CI) 16 13 35.0 % 8.20 [ -5.35, 21.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
2 Pre/6 months
Ramig 1995 13 7.9 (15.7) 9 3.6 (16.8) 33.2 % 4.30 [ -9.60, 18.20 ]
Subtotal (95% CI) 13 9 33.2 % 4.30 [ -9.60, 18.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Pre/12 months
Ramig 1995 13 3.3 (16.5) 9 6.5 (16.9) 31.8 % -3.20 [ -17.43, 11.03 ]
Subtotal (95% CI) 13 9 31.8 % -3.20 [ -17.43, 11.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 42 31 100.0 % 3.28 [ -4.73, 11.30 ]
Heterogeneity: Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 1.32, df = 2 (P = 0.52), I2 =0.0%
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Analysis 1.13. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 13 BDI self rating of
depression.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 13 BDI self rating of depression
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 20 -0.9 (5.4) 15 0.2 (5.4) 70.0 % -1.10 [ -4.72, 2.52 ]
Subtotal (95% CI) 20 15 70.0 % -1.10 [ -4.72, 2.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Pre/12 months
Ramig 1995 14 0.29 (6.6) 11 0.36 (7.3) 30.0 % -0.07 [ -5.60, 5.46 ]
Subtotal (95% CI) 14 11 30.0 % -0.07 [ -5.60, 5.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 34 26 100.0 % -0.79 [ -3.82, 2.23 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 1.14. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 14 SIP
Communication.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 14 SIP Communication
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 20 -17 (18.9) 15 -2.5 (24.4) 64.3 % -14.50 [ -29.37, 0.37 ]
Subtotal (95% CI) 20 15 64.3 % -14.50 [ -29.37, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Pre/12 months
Ramig 1995 14 -4.62 (20) 10 8.14 (27.4) 35.7 % -12.76 [ -32.71, 7.19 ]
Subtotal (95% CI) 14 10 35.7 % -12.76 [ -32.71, 7.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 34 25 100.0 % -13.88 [ -25.80, -1.96 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.15. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 15 SIP social
interaction.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 15 SIP social interaction
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 20 -1.7 (7.02) 15 -1.3 (11.1) 77.3 % -0.40 [ -6.80, 6.00 ]
Subtotal (95% CI) 20 15 77.3 % -0.40 [ -6.80, 6.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 Pre/12 months
Ramig 1995 14 -1.8 (7.8) 10 2.8 (17.9) 22.7 % -4.60 [ -16.42, 7.22 ]
Subtotal (95% CI) 14 10 22.7 % -4.60 [ -16.42, 7.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 34 25 100.0 % -1.35 [ -6.98, 4.28 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 1.16. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 16 Hoarseness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 16 Hoarseness
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 13 -29.8 (22.1) 7 -12.6 (16.4) 100.0 % -17.20 [ -34.29, -0.11 ]
Total (95% CI) 13 7 100.0 % -17.20 [ -34.29, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 17 Breathiness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 17 Breathiness
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ramig 1995 13 -28.1 (30.5) 7 -4.3 (18.9) 100.0 % -23.80 [ -45.50, -2.10 ]
Total (95% CI) 13 7 100.0 % -23.80 [ -45.50, -2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 LSVT versus high respiratory effort treatment, Outcome 18 SPL sustained
phonation.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 1 LSVT versus high respiratory effort treatment
Outcome: 18 SPL sustained phonation
Study or subgroup LSVT RET
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pre/post
Ramig 1995 26 13 (4.7) 19 -1.3 (4.7) 36.9 % 14.30 [ 11.52, 17.08 ]
Subtotal (95% CI) 26 19 36.9 % 14.30 [ 11.52, 17.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.08 (P < 0.00001)
2 Pre/6 months
Ramig 1995 22 9.1 (4.5) 13 -1.5 (5.7) 21.7 % 10.60 [ 6.98, 14.22 ]
Subtotal (95% CI) 22 13 21.7 % 10.60 [ 6.98, 14.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.73 (P < 0.00001)
3 Pre/12 months
Ramig 1995 22 7.9 (4.6) 13 -1.6 (5.3) 23.8 % 9.50 [ 6.04, 12.96 ]
Subtotal (95% CI) 22 13 23.8 % 9.50 [ 6.04, 12.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.38 (P < 0.00001)
4 Pre/24 months
Ramig 1995 21 8.2 (4.3) 12 0.9 (6.3) 17.7 % 7.30 [ 3.29, 11.31 ]
Subtotal (95% CI) 21 12 17.7 % 7.30 [ 3.29, 11.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00036)
Total (95% CI) 91 57 100.0 % 11.12 [ 9.43, 12.81 ]
Heterogeneity: Chi2 = 9.43, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 12.91 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.43, df = 3 (P = 0.02), I2 =68%
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Analysis 2.1. Comparison 2 LSVT Artic versus LSVT Loud, Outcome 1 SPL Reading Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 2 LSVT Artic versus LSVT Loud
Outcome: 1 SPL Reading Pre/Post
Study or subgroup LSVT Artic LSVT Loud
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Halpern 2007 10 1.16 (3.78) 8 6.19 (3.34) 100.0 % -5.03 [ -8.32, -1.74 ]
Total (95% CI) 10 8 100.0 % -5.03 [ -8.32, -1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 LSVT Artic versus LSVT Loud, Outcome 2 DRT Score Babble Noise Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 2 LSVT Artic versus LSVT Loud
Outcome: 2 DRT Score Babble Noise Pre/Post
Study or subgroup LSVT Artic LSVT Loud
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Halpern 2007 10 -0.06 (10.21) 8 12.4 (10.59) 100.0 % -12.46 [ -22.15, -2.77 ]
Total (95% CI) 10 8 100.0 % -12.46 [ -22.15, -2.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours LSVT Loud Favours LSVT Artic
43Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 LSVT Artic versus LSVT Loud, Outcome 3 DRT Score Shopping Mall Noise
Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 2 LSVT Artic versus LSVT Loud
Outcome: 3 DRT Score Shopping Mall Noise Pre/Post
Study or subgroup LSVT Artic LSVT Loud
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Halpern 2007 10 4.42 (11.64) 8 16.06 (15.76) 100.0 % -11.64 [ -24.73, 1.45 ]
Total (95% CI) 10 8 100.0 % -11.64 [ -24.73, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 LSVT Artic versus LSVT Loud, Outcome 4 DRT Score No Noise Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 2 LSVT Artic versus LSVT Loud
Outcome: 4 DRT Score No Noise Pre/Post
Study or subgroup LSVT Artic LSVT Loud
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Halpern 2007 10 -0.46 (3.45) 8 1.6 (4.6) 100.0 % -2.06 [ -5.90, 1.78 ]
Total (95% CI) 10 8 100.0 % -2.06 [ -5.90, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 1 Speech Rate Reading Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 1 Speech Rate Reading Pre/Post
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 -1.1 (0.56) 4 -0.37 (0.36) 100.0 % -0.73 [ -1.33, -0.13 ]
Total (95% CI) 5 4 100.0 % -0.73 [ -1.33, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 2 Speech Rate Reading Pre/6 Week Follow-up.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 2 Speech Rate Reading Pre/6 Week Follow-up
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 -1.02 (0.59) 4 -0.19 (0.31) 100.0 % -0.83 [ -1.43, -0.23 ]
Total (95% CI) 5 4 100.0 % -0.83 [ -1.43, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0067)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 3 Intelligibility Reading Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 3 Intelligibility Reading Pre/Post
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 0.7 (18.89) 5 24.59 (13.93) 100.0 % -23.89 [ -44.46, -3.32 ]
Total (95% CI) 5 5 100.0 % -23.89 [ -44.46, -3.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 4 Intelligibility Reading Pre/6 Week Follow-up.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 4 Intelligibility Reading Pre/6 Week Follow-up
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 9.59 (20.72) 5 15.07 (16.12) 100.0 % -5.48 [ -28.49, 17.53 ]
Total (95% CI) 5 5 100.0 % -5.48 [ -28.49, 17.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 5 Intelligibility Monologue Pre/Post.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 5 Intelligibility Monologue Pre/Post
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 0.44 (1.2) 5 0.34 (2.69) 100.0 % 0.10 [ -2.48, 2.68 ]
Total (95% CI) 5 5 100.0 % 0.10 [ -2.48, 2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy,
Outcome 6 Intelligibility Monologue Pre/6 Week Follow-up.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 3 Altered Auditory Feedback versus Traditional Rate Reduction Therapy
Outcome: 6 Intelligibility Monologue Pre/6 Week Follow-up
Study or subgroup AAF TT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lowit 2010 5 0.14 (1.18) 5 0.1 (2.08) 100.0 % 0.04 [ -2.06, 2.14 ]
Total (95% CI) 5 5 100.0 % 0.04 [ -2.06, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 1 SPL Monologue.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 1 SPL Monologue
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 3.87 (2.27) 17 3.88 (3.24) 100.0 % -0.01 [ -1.89, 1.87 ]
Total (95% CI) 17 17 100.0 % -0.01 [ -1.89, 1.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 2 SPL sustained vowel
phonation.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 2 SPL sustained vowel phonation
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 0.29 (4.01) 17 10.3 (4.42) 100.0 % -10.01 [ -12.85, -7.17 ]
Total (95% CI) 17 17 100.0 % -10.01 [ -12.85, -7.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 3 SPL reading.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 3 SPL reading
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 5.04 (2.85) 17 4.79 (3.07) 100.0 % 0.25 [ -1.74, 2.24 ]
Total (95% CI) 17 17 100.0 % 0.25 [ -1.74, 2.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 4 Duration of phonation.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 4 Duration of phonation
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 0.61 (4.09) 17 0.24 (4.84) 100.0 % 0.37 [ -2.64, 3.38 ]
Total (95% CI) 17 17 100.0 % 0.37 [ -2.64, 3.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 5 Max fundamental frequency
range.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 5 Max fundamental frequency range
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 2.68 (8.11) 17 2.29 (4.94) 100.0 % 0.39 [ -4.12, 4.90 ]
Total (95% CI) 17 17 100.0 % 0.39 [ -4.12, 4.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 6 Breathiness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 6 Breathiness
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 -15.06 (11.34) 17 -20.59 (15.08) 100.0 % 5.53 [ -3.44, 14.50 ]
Total (95% CI) 17 17 100.0 % 5.53 [ -3.44, 14.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 7 Roughness.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 7 Roughness
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 -3.06 (11.17) 17 -12.26 (11.77) 100.0 % 9.20 [ 1.49, 16.91 ]
Total (95% CI) 17 17 100.0 % 9.20 [ 1.49, 16.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours online LSVT Favours face-to-face LSVT
Analysis 4.8. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 8 Loudness level.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 8 Loudness level
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 36.42 (18.29) 17 44.16 (18.86) 100.0 % -7.74 [ -20.23, 4.75 ]
Total (95% CI) 17 17 100.0 % -7.74 [ -20.23, 4.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 9 Loudness variability.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 9 Loudness variability
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 26.23 (9.43) 17 20.85 (14.52) 100.0 % 5.38 [ -2.85, 13.61 ]
Total (95% CI) 17 17 100.0 % 5.38 [ -2.85, 13.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
Analysis 4.10. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 10 Pitch variability.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 10 Pitch variability
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 15.77 (11.55) 17 9.28 (15.43) 100.0 % 6.49 [ -2.67, 15.65 ]
Total (95% CI) 17 17 100.0 % 6.49 [ -2.67, 15.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
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Analysis 4.11. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 11 Overall articulatory
precision.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 11 Overall articulatory precision
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 9.26 (12.37) 17 0.12 (16.49) 100.0 % 9.14 [ -0.66, 18.94 ]
Total (95% CI) 17 17 100.0 % 9.14 [ -0.66, 18.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
Analysis 4.12. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 12 Overall speech
intelligibility in conversation.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 12 Overall speech intelligibility in conversation
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 6.25 (12.37) 17 15.33 (21.17) 100.0 % -9.08 [ -20.74, 2.58 ]
Total (95% CI) 17 17 100.0 % -9.08 [ -20.74, 2.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
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Analysis 4.13. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 13 Percentage word
intelligibility.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 13 Percentage word intelligibility
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 1.93 (4.03) 17 4.06 (11.32) 100.0 % -2.13 [ -7.84, 3.58 ]
Total (95% CI) 17 17 100.0 % -2.13 [ -7.84, 3.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
Analysis 4.14. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 14 Percentage sentence
intelligibility.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 14 Percentage sentence intelligibility
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 1.21 (2.06) 17 2.58 (5.1) 100.0 % -1.37 [ -3.98, 1.24 ]
Total (95% CI) 17 17 100.0 % -1.37 [ -3.98, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
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Analysis 4.15. Comparison 4 Online LSVT versus face-to-face LSVT, Outcome 15 Communication
efficiency ratio.
Review: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease
Comparison: 4 Online LSVT versus face-to-face LSVT
Outcome: 15 Communication efficiency ratio
Study or subgroup Online LSVT Face-to-face LSVT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Constantinescu 2011 17 -0.05 (0.22) 17 -0.05 (0.24) 100.0 % 0.0 [ -0.15, 0.15 ]
Total (95% CI) 17 17 100.0 % 0.0 [ -0.15, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours face-to-face LSVT Favours online LSVT
A D D I T I O N A L T A B L E S
Table 1. Glossary
TERM DEFINITION
Amplitude The maximum absolute value of a periodically varying quantity.
For a sound wave, the maximum variation in pressure relative
to static conditions (e.g. atmospheric pressure). Small variations
produce weak (or quiet) sounds whilst large variations produce
strong (or loud) sounds. (See loudness below)
Articulation The production of vowels and consonants using both the moving
parts of the mouth (e.g. tongue and lips) and the fixed structure
of the mouth (e.g. hard and soft palate). It does not involve the
voice box
Concealment of Allocation The process used to conceal foreknowledge of group assignment,
which should be seen as distinct from blinding. The allocation
process should be impervious to any influence by the person mak-
ing the allocation. Adequate methods of allocation concealment
include: centralised randomisation schemes (telephone randomi-
sation) or sequentially numbered opaque sealed envelopes
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Table 1. Glossary (Continued)
Decibel (dB) A unit used to express relative difference in power or intensity,
usually between two acoustic or electric signals, equal to ten times
the common logarithm (i.e. base 10) of the ratio of the two levels.
i.e. 10 log10 (W2/W1) where W1 is the reference power level
and W2 is the quantity being specified in dB relative to W1. It
is commonplace to want to express in decibels, quantities that
are related not to power, but power2. Examples include sound
pressure and voltage. In such cases the expression for the decibel
level becomes 20 log10 (p2/p1).So that individual quantities can
be specified, default reference values are defined for sound pressure
(20´ 10-6 Pascals), sound power (10-6 watts) and sound intensity
(10-12 watts per square meter). For other quantities (e.g. voltage)
a value of unity is often used implicitly. The reference level for
sound pressure (corresponding to 0 dB) was originally set as an
approximation to the threshold of human hearing. A whisper has
an intensity of ~30 dB, normal speech ~60 dB, a shout ~90 dB
and a jet aircraft ~120 dB
Dysarthria Dysarthria is a collective name for a group of speech disorders re-
sulting fromdisturbances inmuscular control of the speechmech-
anism due to damage of the central nervous system. It designates
problems in oral communication due to paralysis, weakness or
incoordination of the speech musculature
Dysprosody Abnormal prosody (see prosody). Loss of the ’melody’ of speech
Frequency The number of complete cycles of a periodic process occurring
per unit time. For sound waves this is the number of times the
pressure variation cycle occurs in one second. The unit used to
measure frequency is the hertz (Hz) (see below)
Fundamental Frequency (F0) The fundamental frequency is the inverse of the period (T0); i.e.
F0 = 1/T0. For complex sounds such as speech, F0 will normally
correspond to the frequency of the lowest harmonic. It ismeasured
in hertz (see below). The aim of S&LT is to increase the F0 of
Parkinsonian speech as this leads to improved intelligibility. See
also Pitch (see below)
Fundamental Frequency Variability The variation in fundamental frequency (see above) of speech.
Measured as the standard deviation of F0 in hertz or semitones
(STSD). The aim of S&LT is to increase F0 variation and thus
decrease the monotonicity of the patient’s speech. See also Pitch
Hertz (Hz) Hertz is the unit of frequency expressed in cycles (sound waves)
per second
Hypophonia A breathy hoarseness to the speech.
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Table 1. Glossary (Continued)
Intelligibility Degree of clarity with which utterances are understood by average
listeners. It is influenced by articulation, rate, fluency, vocal quality
and intensity (see below)
Intensity (of Sound) The sound power propagating through a unit area of the sound
field in a given direction. For example the sound intensity of a
point source radiating spherical waves and of a given sound power,
will diminish as the distance from the source is increased, in pro-
portion to the inverse of the square of this distance (1/distance2).
It is a vector quantity since it specifies both a magnitude and direc-
tion, therefore direct measurement is not straightforward. Sound
intensity has units of watts per square metre, but can also be ex-
pressed in decibels (see above). Sound intensity is related to the
square of the sound pressure, but the exact relationship depends
on the characteristics of the sound field
Intention-To-Treat Data Analysis Data are analysed according to the randomisation allocation, ir-
respective of protocol violations and withdrawals. Withdrawals,
and therefore missing data points, are usually compensated for by
using the last observation carried forward (LOCF). Intention-to-
treat analyses are favoured in assessments of effectiveness as they
mirror the non-compliance and treatment changes that are likely
to occur when the intervention is used in practice and because of
the risk of attrition bias when participants are excluded from the
analysis
Loudness Loudness can be measured either subjectively or objectively. Sub-
jectively loudness is the perceptual correlate of amplitude (see
above). Equal steps in subjective loudness are roughly equal to
logarithmic steps in amplitude. It is also logarithmically correlated
to intensity, an increase of 6-10 dB is equivalent to a doubling in
perceptual loudness. Objective measurements of loudness mea-
sure the sound’s intensity (see below), usually using the decibel
scale (see above) and are described as Volume or Sound Pressure
Level (see below)
Monotonicity A lack in variation of both loudness (see above) and pitch (see
below)
Palilalia Speaker reiterates many times a word, phrase or sentence which
they have just spoken, sometimes with increasing rate and decreas-
ing audibility
Period (T0) The length of each sound wave (cycle) in time is called the period
of a waveform. It is equal to 1/frequency
Per Protocol Data Analysis Data are analysed according to what therapy the patients received,
rather than according to their randomised allocation.Withdrawals
are removed from the analysis. This form of data analysis risks
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Table 1. Glossary (Continued)
attrition bias
Phonation The mechanism of producing sounds with the vocal folds (also
known as vocal cords)
Pitch The perceptual correlate of frequency (see above). Normally, the
pitch of a complex sound is a function of its fundamental fre-
quency (see above). Equal steps in pitch are roughly equal to log-
arithmic steps in amplitude
Prosody Prosody is defined as that aspect of spoken language which con-
sists in correct placing of pitch and stress on syllables and words. It
is responsible for conveying subtle changes of meaning indepen-
dently of words or grammatical order. In addition to this semantic
role, it makes a major contribution to the emotional content of
speech
Rainbow Passage A reading passage that is phonetically balanced and has all the
vowel and consonant sounds present in the English language
Reference values for sound pressure, sound power and sound in-
tensity (P0)
So that individual quantities can be specified in terms of decibels,
default reference values are defined for sound pressure (20´ 10-
6 Pascals), sound power (10-6 watts) and sound intensity (10-
12 watts per square meter). For other quantities (e.g. voltage)
a value of unity is often used implicitly. The reference level for
sound pressure (corresponding to 0 dB) was originally set as an
approximation to the threshold of human hearing. However this
equivalence has since been questioned
Respiration Breathing
Sound Pressure and Sound Pressure Level (SPL) Sound pressure is the root mean square (r.m.s) variation in pres-
sure from the static value (e.g. the atmospheric pressure) and is
measured in Pascals. The r.m.s variation in pressure from the static
value (e.g. the atmospheric pressure). Sound pressure is measured
in Pascals, but can be expressed in decibels (see above), 20 log10
(sound pressure/20´ 10-6) whereupon it is referred to as sound
pressure level. Sound pressure is a scalar quantity and is therefore
relatively easy to measure, for example a microphone responds
to sound pressure. The reference level for sound pressure (corre-
sponding to 0 dB) was originally set as an approximation to the
threshold of human hearing. However this equivalence has since
been questioned
Volume Equivalent to loudness (see above).
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Table 2. Key Characteristics of Included Studies
Study Number of pa-
tients analysed
Mean age Mean Hoehn &
Yahr score
Duration of ther-
apy
Therapy A Therapy B
Constantinescu
2011
34 70 1.6 16 hours/1 month LSVT - online de-
livery
LSVT - face-to-
face delivery
Halpern 2007 18 68 not reported 13 hours 20 mins/
1 month
LSVT ARTIC -
enhanced articula-
tion
LSVT LOUD -
increased loudness
Healy 2002 26 66 not reported 1 hour session or 6
hour long sessions
over 6 weeks
Alphabet board Pacing board
Lowit 2010 10 63 2.9 6 hours/6 weeks Altered audi-
tory feedback - in
ear device
Traditional rate re-
duction therapy
Ramig 1995 45 65 2.5 16 hours/1 month LSVT - increased
loudness
Respiration ther-
apy
Scott 1983 26 66 n/a 10 hours/2 weeks Prosodic exercises
with visual feed-
back
Prosodic exercises
alone
Total 159
LSVT: Lee Silverman Voice Treatment
Table 3. Summary of Interventions
Intervention Used in Trials Descrip-
tion of inter-
vention
Target Symp-
tom
Duration/
Dose
Treatment
Setting
Designed
specifically
for treatment
of PD
Delivered by
trained thera-
pist Yes/No
Lee Sil-
verman Voice
Therapy
(LSVT)
Ramig 95
Halpern 2007
Constanti-
nescu 2011
A high effort
inten-
sive treatment
using tasks
such as push-
ing hands to-
gether, push-
ing down or
lifting on the
arms of a chair
while phonat-
ing to stimu-
Quiet voice 4 sessions per
week for
4 weeks with
each session
lasting 1 hour
(16 hours)
Ramig 95:
Outpatients
Halpern
2007: Not
reported Con-
stantinescu
2011: Outpa-
tients
YES YES
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Table 3. Summary of Interventions (Continued)
late increased
vo-
cal fold adduc-
tion. Patients
were cued to
think LOUD
and encour-
aged to use
the same loud,
good qual-
ity voice gen-
erated by sus-
tained phona-
tion during
speech tasks
Ar-
ticulation fo-
cussed LSVT
(LSVT-
ARTIC)
Halpern 2007 Follow-
ing same gen-
eral principles
as
LSVT but sus-
tained phona-
tion tasks are
replaced
with articula-
tion drills such
as repitition of
sounds ’pa’, ’ta’
and ’ka’, cue
used for
speech tasks is
ENUNCI-
ATE
Poor articula-
tion
4 sessions per
week for
4 weeks with
each session
lasting 1 hour
(16 hours)
Not reported YES YES
Respiratory
Therapy
Ramig 1995 High effort in-
ten-
sive treatment
aimed at in-
creased respi-
ratory muscle
activity. Tasks
included max-
imising
inhalation and
exhalation,
maximum du-
ra-
tion of voice-
less continu-
Reduced res-
piratory effort
4 sessions per
week for
4 weeks with
each session
lasting 1 hour
(16 hours)
Outpatients NO YES
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Table 3. Summary of Interventions (Continued)
ents /s/ and
/f/ and sus-
tained intrao-
ral air pres-
sure. Visual
feed-
back of excur-
sion of ribcage
and abdomen
during vocal
tasks was pro-
vided. No at-
tentionwas di-
rected toward
increasing vo-
cal loudness
Alphabet
Board
Healy 2002 Board
with grid con-
taining letters
of the alphabet
in
order is used.
Speaker points
to initial letter
of each word
they speak on
the board
Palilalia 6 sessions over
6 weeks OR
a single ses-
sion, each ses-
sion lasting 1
hour (6 hours
OR 1 hour)
Home NO YES
Pacing Board Healy 2002 Wooden ruler
with
series of raised
divisions at 30
mm intervals.
Speaker is re-
quired to place
their finger in
each sec-
tion consecu-
tively as they
speak each
word. Tactile
feedback helps
to control
speech rate
Palilalia 6 sessions over
6 weeks OR
a single ses-
sion, each ses-
sion lasting 1
hour (6 hours
OR 1 hour)
Home YES YES
Altered Audi-
tory Feed-
back (AAF)
Lowit 2010 In-ear device
is worn which
disrupts the
normal audi-
Palilalia 6 sessions over
6 weeks with
each
Home NO UNCLEAR
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Table 3. Summary of Interventions (Continued)
tory feedback
loop causing
the speaker to
hear their
speech in an
altered fashion
reducing rate
of speech. Pa-
tients trialled
both delayed
auditory feed-
back (DAF)
which delivers
speech signal
to speaker af-
ter a short de-
lay and fre-
quency shifted
feedback
(FSF) which
delivers signal
in real time
but with an al-
tered pitch
session lasting
approx. 1 hour
(6 hours)
Traditional
Rate Reduc-
tion Therapy
(TT)
Lowit 2010 Focussed
on identifying
most suitable
strategy for re-
ducing speech
rate e.g. in-
creas-
ing pauses or
stretching out
articula-
tion. Tasks in-
creased
in complexity
heirarchically
from reading
short phrases
to conversa-
tional speech.
Self appraisal
through feed-
back and lis-
ten-
ing to record-
ings was devel-
Palilalia 6 sessions over
6 weeks with
each
session lasting
approx. 1 hour
(6 hours)
Home YES YES
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Table 3. Summary of Interventions (Continued)
oped. Other
speech aspects
such as vol-
ume or into-
national varia-
tion were also
ad-
dressed where
necessary
Prosodic Ex-
ercises (PE)
with Cueing
Scott 83 Ex-
ercises aimed
to increase pa-
tients aware-
ness of speech
problem, em-
phasis-
ing the impor-
tance of vol-
ume and in-
tonation and
using a visual
feedback sys-
tem (vocalite -
a voice-
operated light
source)
Prosodic
abnormality
5 ses-
sions per week
for two weeks
with each ses-
sion
lasting 1 hour
(10 hours)
Home UNCLEAR YES
Prosodic Ex-
ercises (PE)
without Cue-
ing
Scott 83 Same exercises
used in
PE with cue-
ing but with-
out use of vo-
calite
Prosodic
abnormality
5 ses-
sions per week
for two weeks
with each ses-
sion
lasting 1 hour
(10 hours)
Home UNCLEAR YES
Table 4. Summary of Results - Scott 83
Subsection Outcome Mean Difference pre-/post-treatment
General Prosodic abnormality score -0.25
Intelligibility Rating score (0-3) 0.25
Visual analogue scale (0-100) 21.4
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Table 4. Summary of Results - Scott 83 (Continued)
Mean Difference = (Mean change due to
PE + cues) - (Mean change due to PE alone)
No statistical analysis available for mean
change.
Table 5. Summary of Results - Ramig 95
Subsec-
tion
Out-
come
Mean
Differ-
ence pre/
post
treat-
ment
95%
CI pre-/
post-
treat-
ment
P value
pre-/
post-
treat-
ment
Mean
Differ-
ence pre-
/12
month
follow-
up
95% CI
pre-/12
month
follow-
up
P value
pre-/12
month
follow-
up
Mean
Differ-
ence pre-
/24
month
follow-
up
95% CI
pre/24
month
follow-
up
P value
pre-/24
month
follow-
up
Intelligi-
bility
Patient
assessed
3.6 -7.0, 14.2 0.50
Carer as-
sessed
10.7 -7.2, 28.6 0.24
Loudness Patien as-
sessed
3.3 -10.7, 17.
3
0.64
Carer as-
sessed
1.6 -19.9, 23.
1
0.88
Mono-
logue
2.9 0.6, 5.7 0.01 3.8 1.2, 6.4 0.004 1.3 -2.0, 4.6 0.44
Reading 5.5 3.4, 7.7 < 0.
00001
2.8 0.2, 5.4 0.03 2.9 -0.3, 6.1 0.08
Sustained
phona-
tion
14.3 11.5, 17.
1
< 0.
00001
9.5 6.0, 13.0 < 0.
00001
7.3 3.3, 11.3 0.0004
Mono-
tonicity
Patient
assessed
8.7 -4.6, 22.0 0.2
Care as-
sessed
3.1 -19.0, 25.
2
0.78
Mono-
logue
0.5 0.01, 0.9 0.04 0.8 0.1, 1.4 0.02 0.8 0.1, 1.5 0.03
Reading 0.3 0.0, 0.6 0.07 0.3 -0.1, 0.7 0.12 0.2 -0.1, 0.6 0.2
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Table 5. Summary of Results - Ramig 95 (Continued)
Pitch Mono-
logue
8.2 -5.4, 21.8 0.24 -3.2 -17.4, 11.
0
0.6
Reading 4.9 -7.4, 17.2 0.43 2.9 -11.2, 17.
0
0.7
ADL SIP
- commu-
nication
-14.5 -29.4, 0.4 0.06 -12.8 -32.7, 7.2 0.21
SIP - so-
cial inter-
action
-0.4 -6.8, 6.0 0.9 -4.6 -16.4, 7.2 0.45
Depres-
sion
BDI -1.1 -4.7, 2.5 0.55 -0.1 -5.6, 5.5 0.98
Hoarse-
ness
Therapist
assessed
-17.2 -34.3, -0.
1
0.05
Breathi-
ness
Therapist
assessed
-23.8 -45.5, -2.
1
0.03
Mean
Change =
(Mean
change
due
to LSVT)
- (Mean
change
due
to Respi-
ration)
ADL: activities of daily living
BDI: Beck Depression Index
LSVT: Lee Silverman Voice Treatment
SIP: Sickness Impact Profile
Table 6. Summary of Results - Halpern 2007
Subsection Outcome Mean Difference pre-/
post-treatment
95% CI pre-/post-treat-
ment
P value pre-/post-treat-
ment
Loudness Reading -5.0 -8.3, -1.7 0.003
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Table 6. Summary of Results - Halpern 2007 (Continued)
Intelligibility DRT babble noise -12.5 -22.2, -2.8 0.01
DRT shopping mall noise -11.6 -24.7, 1.5 0.08
DRT no noise -2.1 -5.9, 1.8 0.29
DRT: Diagnostic Rhyme Test
Table 7. Summary of Results - Lowit 2010
Subsection Outcome Mean Differ-
ence pre-/
post-
treatment
95% CI pre-/
post-
treatment
P value pre-/
post-
treatment
Mean Differ-
ence pre-/
12 month fol-
low-up
95% CI pre-/
12 month fol-
low-up
P value pre-/
12 month fol-
low-up
Articulation
Rate
Reading -0.7 -1.3, -0.2 0.01 -0.8 -1.4, -0.2 0.007
Intelligibility Reading -23.9 -44.5, -3.3 0.02 -5.5 -28.5, 17.5 0.64
Monologue 0.1 -2.5, 2.7 0.94 0.0 -2.1, 2.1 0.97
CI: confidence interval
Table 8. Summary of Results - Constantinescu 2011
Subsection Outcome Mean Difference pre-/
post-treatment
95% CI pre-/post-
treatment
P value pre-/post-treat-
ment
Intelligibility Overall articulatory pre-
cision
9.1 -0.7, 18.9 0.07
Overall speech intelligi-
bility in conversation
-9.1 -20.7, 2.6 0.13
Percentage word intelli-
gibility
-2.1 -7.8, 3.6 0.46
Percentage sentence in-
telligibility
-1.4 -4.0, 1.2 0.30
Communication
efficiency ratio
0.0 -0.2, 0.2 1.00
Loudness Reading 0.3 -1.7, 2.2 0.81
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Table 8. Summary of Results - Constantinescu 2011 (Continued)
Monologue 0.0 -1.9, 1.9 0.99
Sustained phonation -10.0 -12.9, -7.2 < 0.00001
Monotonicity Vocal glides 0.4 -4.1, 4.9 0.87
Therapist assessed 6.5 -2.7, 15.7 0.17
Duration of phonation Sustained phonation 0.4 -2.7, 3.4 0.81
Loudness level Therapist assessed -7.7 -20.2, 4.8 0.22
Loudness variability Therapist assessed 5.4 -2.9, 13.6 0.20
Roughness Therapist assessed 9.2 1.5, 16.9 0.02
Breathiness Therapist assessed 5.5 -3.4, 14.5 0.23
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Parkinson disease/
13. Parkinson$.tw.
14. 12 or 13
15. exp speech disorders/
16. exp articulation disorders/
17. dysarthr*.tw.
18. (speech or speak*).tw.
19. intelligib*.tw.
20. dysprod*.tw.
21. hypophoni*.tw.
22. monoton*.tw.
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23. phon*.tw.
24. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. exp “rehabilitation of speech and language disorders”/ or exp language therapy/ or exp myofunctional therapy/ or exp speech,
alaryngeal/ or exp speech, esophageal/ or exp speech therapy/ or exp voice training/
26. ((speech or speak* or language or voice or vocal* or articulate* or sing*) adj3 (task* or therap* or treat* or train* or counsel*
or intervention* or exercise* or drill)).tw.
27. (Silverman* or LSVT).tw.
28. 25 or 26 or 27
29. 11 and 14 and 24 and 28
30. 11 and 14 and 28
31. 29 or 30
WH A T ’ S N E W
Last assessed as up-to-date: 3 January 2011.
Date Event Description
9 July 2012 New citation required but conclusions have not changed New citation: conclusions not changed
9 July 2012 New search has been performed Searches hadbeen rerun andnew studieswere incorporated
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 2, 2001
Date Event Description
14 October 2010 Amended This review is currently being updated. In the mean-
time, readers should note that the data reviewed in it
goes back up to 2000. New evidence might have been
published subsequent to the current version. This new
evidence will be evaluated during the updating process
13 November 2008 Amended Converted to new review format.
28 February 2001 New citation required and conclusions have changed Substantive amendment
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